Journal articleCells · July 20, 2026
BACKGROUND/OBJECTIVES: Chronic lymphocytic leukemia (CLL) is characterized by clinical and biological heterogeneity shaped by intrinsic signaling programs and microenvironmental interactions. Established biomarkers, including IGHV mutation status and TP53 ...
Full textOpen AccessLink to itemCite
Journal articleDisaster Med Public Health Prep · March 24, 2026
Dr. C. Norman Coleman, a distinguished cancer specialist and researcher, brought a passion for addressing health disparities to all of his roles from being on the faculty as a Radiation Oncologist at Stanford, as Chair of the Joint Center for Radiation Onc ...
Full textLink to itemCite
Journal articleDisaster Med Public Health Prep · February 6, 2026
This paper addresses the challenges and preparedness strategies for health care systems in responding to nuclear and radiological emergencies. It emphasizes the critical role of medical centers in pre-incident preparedness, immediate response, and long-ter ...
Full textLink to itemCite
Journal articleMicroorganisms · January 28, 2026
In patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), emerging evidence suggests that the oral microbiota may serve as a predictive biomarker. We conducted a systematic review to provide a critical overview of oral microbio ...
Full textLink to itemCite
Journal articleTransplant Cell Ther · January 2026
BACKGROUND: Chlorhexidine gluconate (CHG) bathing is recommended for infection prevention in hematopoietic cell transplantation (HCT) patients. As more centers transition HCT care to outpatient settings, understanding patients' perceptions of CHG bathing f ...
Full textLink to itemCite
Journal articleTransfus Apher Sci · December 2025
BACKGROUND: This study, conducted among collection and transplant centers in France, Germany, Japan, the United Kingdom (UK), and the United States (USA), aimed to better understand current trends, challenges, and future directions in cell collection and a ...
Full textLink to itemCite
Journal articleJ Clin Med · November 24, 2025
Background: Although Enterococcus domination has been extensively evaluated in the context of allogeneic hematopoietic stem cell transplantation (allo-HSCT), the prevalence and clinical implications of other dominant genera remain poorly understood. Object ...
Full textLink to itemCite
Journal articleAdv Sci (Weinh) · November 2025
Human thioredoxin-1 (TRX) is a target-selective disulfide reductase with antioxidant, anti-inflammatory, and regulatory functions that mitigates cellular stresses in various organ systems, providing a compelling rationale for therapeutic use as a broad-spe ...
Full textOpen AccessLink to itemCite
Journal articleRadiat Res · September 1, 2025
The Centers for Medical Countermeasures against Radiation Consortium (CMCRC) has provided a strong research foundation for the radiobiology science that will follow. After 20 years, however, the CMCRC will continue to conduct research on preparedness in ni ...
Full textLink to itemCite
Journal articleBone Marrow Transplant · June 2025
Food insecurity (FI), defined as the lack of continuous access to adequate food, affects 17-55% of cancer patients. Effects may be exacerbated in hematopoietic stem cell transplant (HSCT) patients, who face nutritional challenges due to treatment side effe ...
Full textLink to itemCite
Journal articleBlood Adv · May 13, 2025
Gut dysbiosis is linked to mortality and the development of graft-versus-host disease after hematopoietic stem cell transplantation (HSCT), but the impact of cutaneous dysbiosis remains unexplored. We performed a pilot observational study, obtained retroau ...
Full textLink to itemCite
Journal articleCancers (Basel) · March 29, 2025
Background/Objectives: Informed consent is a crucial part of the clinical trial enrollment process in which patients are asked to understand and provide approval for medical interventions. Consent forms can be complex and hinder patient comprehension, high ...
Full textLink to itemCite
Journal articlePeerJ · 2025
Recent studies have linked beta-blocker (BB) use in critical care settings with improved survival outcomes, potentially due to beta-adrenergic receptor (β-AR) blockade and associated anti-inflammatory effects. Given the immune system's role in the developm ...
Full textLink to itemCite
Journal articleOBM Transplant · 2025
Home-based hematopoietic stem cell transplantation (HCT) is an innovative care model with growing interest, but its impact on the gut microbiome remains unexplored in a randomized setting. We present interim results from the first randomized controlled tri ...
Full textLink to itemCite
Journal articleSupport Care Cancer · November 28, 2024
UNLABELLED: Hematopoietic cell transplantation (HCT) is a promising treatment for hematologic malignancies, but intensive conditioning leads to immunosuppression and susceptibility to healthcare-associated infections (HAI). Despite standard prevention meas ...
Full textLink to itemCite
Journal articleRadiat Res · August 1, 2024
Extracellular vesicles (EVs) have been recognized as a novel way of cell-to-cell communication in the last several decades. It is believed that EVs exert their functions on nearby or distant cells through transfer of the cargo that they carry. In this revi ...
Full textLink to itemCite
Journal articleNat Commun · July 17, 2024
Type II innate lymphoid cells (ILC2s) maintain homeostasis and barrier integrity in mucosal tissues. In both mice and humans, ILC2s poorly reconstitute after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Determining the mechanisms involve ...
Full textLink to itemCite
Journal articleTransplant Cell Ther · June 2024
A shortage of transplant and cellular therapy (TCT) physicians is expected given the expansion of TCT indications and the scope of practice of TCT programs in recent years. American Society of Transplantation and Cellular Therapy (ASTCT) conducted a survey ...
Full textLink to itemCite
Journal articleTransplant Cell Ther · May 2024
We provide a summary of the 4th ASTCT International Workshop with presentations from experts from Chile ("Setting Up a Transplantation Program in Chile," by Dr Pablo Ramirez), Saudi Arabia ("Developing Quality Programs in North Africa," by Dr Amal Alseraih ...
Full textLink to itemCite
Journal articleTransplant Cell Ther · April 2024
Hematologic malignancies disproportionately affect older adults. Hematopoietic cell transplantation (HCT) is potentially curative, but poor overall survival (OS) has limited its use in older adults. Fried's frailty phenotype (FFP) is a geriatric assessment ...
Full textLink to itemCite
Journal articleJCO Oncol Pract · March 2024
PURPOSE: We investigated the prevalence of financial toxicity in a population undergoing hematopoietic cell transplantation (HCT) evaluation and measured its impact on post-transplant clinical and health-related quality-of-life outcomes. MATERIALS AND METH ...
Full textLink to itemCite
Journal articleBlood advances · February 2024
AbstractChronic graft-versus-host disease (cGVHD) is a debilitating, autoimmune-like syndrome that can occur after allogeneic hematopoietic stem cell transplantation. Constitutively activated B cells contribute to ongoing alloreactivity and autore ...
Full textOpen AccessCite
Journal articleGut Microbes · 2024
Antibiotic resistance is a global threat driven primarily by antibiotic use. We evaluated the effects of antibiotic exposures on the gut microbiomes and resistomes of children at high risk of colonization by antibiotic-resistant bacteria. We performed shot ...
Full textLink to itemCite
Journal articleFront Immunol · 2024
The thymus is the central organ involved with T-cell development and the production of naïve T cells. During normal aging, the thymus undergoes marked involution, reducing naïve T-cell output and resulting in a predominance of long-lived memory T cells in ...
Full textLink to itemCite
Journal articleProc Natl Acad Sci U S A · December 12, 2023
Thrombocytopenia, hemorrhage, anemia, and infection are life-threatening issues following accidental or intentional radiation exposure. Since few therapeutics are available, safe and efficacious small molecules to mitigate radiation-induced injury need to ...
Full textLink to itemCite
Journal articleJCI Insight · June 8, 2023
Alloreactivity can drive autoimmune syndromes. After allogeneic hematopoietic stem cell transplantation (allo-HCT), chronic graft-versus-host disease (cGVHD), a B cell-associated autoimmune-like syndrome, commonly occurs. Because donor-derived B cells cont ...
Full textOpen AccessLink to itemCite
Journal articleCell · June 8, 2023
Discerning the effect of pharmacological exposures on intestinal bacterial communities in cancer patients is challenging. Here, we deconvoluted the relationship between drug exposures and changes in microbial composition by developing and applying a new co ...
Full textLink to itemCite
Journal articleJCO Glob Oncol · June 2023
PURPOSE: Over 400,000 children are diagnosed with cancer around the world each year, with over 80% of these children residing in low- and middle-income countries. This study aims to summarize the epidemiology and care patterns of newly diagnosed childhood ...
Full textLink to itemCite
Journal articleHeliyon · April 2023
Recent studies have shown that microtransplant (MST) could improve outcome of patients with elderly acute myeloid leukemia (EAML). To further standardize the MST therapy and improve outcomes in EAML patients, based on analysis of the literature on MST, esp ...
Full textLink to itemCite
Journal articleAnnals of Internal Medicine Clinical Cases · April 1, 2023
Lower-extremity ulcerations are a frequent cause of hospitalization, and those that persist despite appropriate treatment warrant careful scrutiny. We present a case of chronic, progressive leg ulcerations in a young woman accompanied by oral and genital u ...
Full textCite
Journal articleTransplant Cell Ther · March 2023
Despite the exciting advancement of novel therapies, chronic graft-versus-host disease (cGVHD) remains the most common cause of non-relapse mortality after allogeneic hematopoietic stem cell transplantation (HCT). Frontline treatment of cGVHD involves syst ...
Full textLink to itemCite
Journal articleClin Cancer Res · January 4, 2023
PURPOSE: The gut microbiota is subject to multiple insults in allogeneic hematopoietic cell transplantation (allo-HCT) recipients. We hypothesized that preparative conditioning regimens contribute to microbiota perturbation in allo-HCT. EXPERIMENTAL DESIGN ...
Full textLink to itemCite
Journal articleBlood · November 24, 2022
Previous studies suggest that gut microbiome disruption induced by chemotherapy, dietary deficiencies, and/or antibiotics are associated with increased incidence of acute graft-versus-host disease (aGVHD) following hematopoietic stem cell transplantation ( ...
Full textLink to itemCite
Journal articleTranspl Infect Dis · August 2022
BACKGROUND: Allogeneic hematopoietic cell transplant (allo-HCT) recipients are at increased risk for respiratory viral infections (RVIs), which invoke substantial morbidity and mortality. Limited effective antiviral options and drug resistance often hamper ...
Full textLink to itemCite
Journal articleTransplant Cell Ther · August 2022
Allogeneic hematopoietic stem cell transplantation (HCT) is a potentially curative treatment for both malignant and nonmalignant hematologic diseases; however, reported rates of treatment-related mortality approach 30%. Outcomes are worse in patients who b ...
Full textLink to itemCite
Journal articleSci Transl Med · May 25, 2022
Microbial diversity is associated with improved outcomes in recipients of allogeneic hematopoietic cell transplantation (allo-HCT), but the mechanism underlying this observation is unclear. In a cohort of 174 patients who underwent allo-HCT, we demonstrate ...
Full textLink to itemCite
Journal articleTransplant Cell Ther · April 2022
Patients undergoing allogeneic (allo) and autologous (auto) hematopoietic cell transplantation (HCT) require extensive hospitalizations or daily clinic visits for the duration of their transplantation. Home HCT, wherein patients live at home and providers ...
Full textLink to itemCite
Journal articleOpen Forum Infect Dis · February 2022
BACKGROUND: Cytomegalovirus (CMV) causes substantial morbidity and mortality after hematopoietic stem cell transplantation (HSCT). There are limited data on risk factors for CMV viremia and the safety of antiviral medications used to treat CMV in children. ...
Full textLink to itemCite
Journal articleBlood Adv · January 11, 2022
The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approac ...
Full textLink to itemCite
Journal articleFront Immunol · 2022
Alloreactive donor T cells undergo extensive metabolic reprogramming to become activated and induce graft-versus-host disease (GVHD) upon alloantigen encounter. It is generally thought that glycolysis, which promotes T cell growth and clonal expansion, is ...
Full textLink to itemCite
Journal articlePLoS One · 2022
INTRODUCTION: In order to study the role of the microbiome in hematopoietic stem cell transplantation (HCT), researchers collect stool samples from patients at various time points throughout HCT. However, stool collection requires active subject participat ...
Full textLink to itemCite
Journal articlePLoS One · 2022
Although hematopoietic stem cell transplantation (HCT) is the only curative treatment for acute myeloid leukemia (AML), it is associated with significant treatment related morbidity and mortality. There is great need for predictive biomarkers associated wi ...
Full textLink to itemCite
Journal articlePLoS One · 2022
BACKGROUND: Worldwide, an estimated 400,000 children develop cancer each year. The bulk of the mortalities from these cases occur in low-and-middle-income countries (LMICs). In Sub-Saharan Africa, there is a tremendous need to strengthen the capacity of he ...
Full textLink to itemCite
Journal articleClin Infect Dis · December 20, 2021
BACKGROUND: Enterococcus intestinal domination (EID), a state of dysbiosis wherein enterococci comprise ≥30% abundance within the microbiota, has been associated with Enterococcus bacteremia, graft-versus-host disease, and mortality in the allogeneic hemat ...
Full textLink to itemCite
Journal articleBone Marrow Transplant · December 2021
Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS), a potentially life-threatening complication of hematopoietic cell transplantation (HCT), results from prolonged sinusoidal endothelial cell activation and profound endothelial cell d ...
Full textLink to itemCite
Journal articleComprehensive Cancer Center Development Integration and Implementation · October 28, 2021
Cancer is a growing healthcare problem worldwide with significant public health and economic burden to both developed and developing countries. According to the World Health Organization, cancer is the second leading cause of death globally, with an estima ...
Full textCite
Journal articleBone Marrow Transplant · September 2021
Acute myeloid leukemia (AML) patients often undergo allogeneic hematopoietic cell transplantation (alloHCT) in first complete remission (CR). We examined the effect of depth of clinical response, including incomplete count recovery (CRi) and/or measurable ...
Full textLink to itemCite
Journal articleTransplant Cell Ther · September 2021
Life expectancy for long-term survivors of allogeneic hematopoietic stem cell transplantation (alloHSCT), defined as those living ≥5 years post-transplantation, is significantly lower compared with that of the age-matched general population despite a relat ...
Full textLink to itemCite
Journal articleTransplant Cell Ther · August 2021
Allogeneic hematopoietic stem cell transplantation (HCT) has the potential to cure hematologic malignancies but is associated with significant morbidity and mortality. Although deaths during the first year after transplantation are often attributable to tr ...
Full textOpen AccessLink to itemCite
Journal articleClin J Oncol Nurs · August 1, 2021
BACKGROUND: Healthcare delivery has been significantly changed because of the COVID-19 pandemic. Patients undergoing hematopoietic stem cell transplantation (HSCT) are vulnerable to infections because of their immunocompromised status. The risk of nosocomi ...
Full textLink to itemCite
Journal articleBlood · May 6, 2021
Patients with chronic graft-versus-host disease (cGVHD) have increased B cell-activating factor (BAFF) levels, but whether BAFF promotes disease after allogeneic bone marrow transplantation (allo-BMT) remains unknown. In a major histocompatibility complex- ...
Full textLink to itemCite
Journal articleBlood · March 18, 2021
We previously described clinically relevant reductions in fecal microbiota diversity in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT). Recipients of high-dose chemotherapy and autologous HCT (auto-HCT) incur similar antibioti ...
Full textLink to itemCite
Journal articleTransplant Cell Ther · March 2021
Bloodstream infections (BSIs) occur in 20% to 45% of inpatient autologous and allogeneic hematopoietic cell transplant (HCT) patients. Daily bathing with the antiseptic chlorhexidine gluconate (CHG) has been shown to reduce the incidence of BSIs in critica ...
Full textLink to itemCite
Journal articleTransplant Cell Ther · March 2021
Establishing a hematopoietic cell transplantation (HCT) program is complex. Planning is essential while establishing such a program to overcome the expected challenges. Authorities involved in HCT program establishment will need to coordinate the efforts b ...
Full textLink to itemCite
Journal articleTransplant Cell Ther · February 2021
Hematopoietic stem cell transplantation (HCT) is a curative treatment option for patients with hematologic conditions but presents many complications that must be managed as a complex, chronic condition. Mobile health applications (mHealth apps) may permit ...
Full textLink to itemCite
Journal articleBone Marrow Transplant · January 2021
Prophylactic donor lymphocyte infusions (DLI) are used to augment post-transplant immune recovery to reduce both infectious complications and disease recurrence. Preclinical studies implicate the naive T-cell subset as the primary driver of graft-versus-ho ...
Full textLink to itemCite
Journal articlePLoS One · 2021
BACKGROUND: Allogeneic hematopoietic stem cell transplantation (HCT) is an often curative intent treatment, however it is associated with significant gastrointestinal (GI) toxicity and treatment related mortality. Graft-versus-host disease is a significant ...
Full textLink to itemCite
Journal articleFront Immunol · 2021
Myeloid-derived suppressor cells (MDSCs) are a hetero geneous group of cells, which can suppress the immune response, promote tumor progression and impair the efficacy of immunotherapies. Consequently, the pharmacological targeting of MDSC is emerging as a ...
Full textLink to itemCite
Journal articleGlob Health Sci Pract · December 23, 2020
The undeniable benefit of mentorship by experience senior mentors can meaningfully increase the breadth of their experience and contributions to society as well as address the dire inequality in global health. This model captures wisdom lost to retirement, ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · December 2020
Delirium is common among adults undergoing hematopoietic stem cell transplantation (HCT), although the clinical and neuroimaging correlates of post-HCT delirium have not been adequately delineated. We therefore examined the frequency of delirium and neuroi ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · December 2020
The current COVID-19 pandemic, caused by SARS-CoV-2, has impacted many facets of hematopoietic cell transplantation (HCT) in both developed and developing countries. Realizing the challenges as a result of this pandemic affecting the daily practice of the ...
Full textLink to itemCite
Journal articleNature · December 2020
The gut microbiota influences development1-3 and homeostasis4-7 of the mammalian immune system, and is associated with human inflammatory8 and immune diseases9,10 as well as responses to immunotherapy11-14. Nevertheless, our understanding of how gut bacter ...
Full textLink to itemCite
Journal articleScience · October 30, 2020
Ionizing radiation causes acute radiation syndrome, which leads to hematopoietic, gastrointestinal, and cerebrovascular injuries. We investigated a population of mice that recovered from high-dose radiation to live normal life spans. These "elite-survivors ...
Full textLink to itemCite
Journal articleBr J Haematol · September 2020
Sinusoidal obstruction syndrome (SOS), previously known as hepatic veno-occlusive disease (VOD), remains a multi-organ system complication following haematopoietic cell transplantation (HCT). When SOS/VOD is accompanied by multi-organ dysfunction, overall ...
Full textLink to itemCite
Journal articleBr J Haematol · August 2020
Use of haematopoietic cell transplantation (HCT) in the treatment of haematologic and neoplastic diseases may lead to life-threatening complications that cause substantial morbidity and mortality if untreated. In addition to patient- and disease-related fa ...
Full textLink to itemCite
Journal articleCancer Epidemiol · August 2020
PURPOSE: To describe cancer incidence and treatment utilization patterns at the regional cancer referral center for the Lake Zone of northwestern Tanzania from 2008 to 2016. METHODS: This descriptive, retrospective study reviewed all cancer cases recorded ...
Full textLink to itemCite
Journal articleRadiat Res · August 1, 2020
Thrombocytopenia (TCP) may cause severe and life-threatening bleeding. While this may be prevented by platelet transfusions, transfusions are associated with potential complications, do not always work (platelet refractory) and are not always available. Th ...
Full textLink to itemCite
Journal articleBlood · July 2, 2020
Studies of the relationship between the gastrointestinal microbiota and outcomes in allogeneic hematopoietic stem cell transplantation (allo-HCT) have thus far largely focused on early complications, predominantly infection and acute graft-versus-host dise ...
Full textLink to itemCite
Journal articleAm J Hematol · June 2020
Older AML patients have low remission rates and poor survival outcomes with standard chemotherapy. Microtransplantation (MST) refers to infusion of allogeneic hematopoietic stem cells without substantial engraftment. MST has been shown to improve clinical ...
Full textLink to itemCite
Journal articleHaematologica · May 2020
Cytogenetic risk stratification at diagnosis has long been one of the most useful tools to assess prognosis in acute lymphoblastic leukemia (ALL). To examine the prognostic impact of cytogenetic abnormalities on outcomes after allogeneic hematopoietic cell ...
Full textLink to itemCite
Journal articleAdv Sci (Weinh) · March 2020
The roles of mitochondrial dysfunction in carcinogenesis remain largely unknown. The effects of PTEN-induced putative kinase 1 (PINK1)-dependent mitophagy on the pathogenesis of multiple myeloma (MM) are determined. The levels of the PINK1-dependent mitoph ...
Full textLink to itemCite
Journal articleN Engl J Med · February 27, 2020
BACKGROUND: Relationships between microbiota composition and clinical outcomes after allogeneic hematopoietic-cell transplantation have been described in single-center studies. Geographic variations in the composition of human microbial communities and dif ...
Full textLink to itemCite
Journal articleInt J Radiat Biol · January 2020
Purpose: Design and characterization of a radiation biodosimetry device are complicated by the fact that the requisite data are not available in the intended use population, namely humans exposed to a single, whole-body radiation dose. Instead, one must tu ...
Full textLink to itemCite
Journal articleInt J Radiat Biol · January 2020
PURPOSE: We introduce and evaluate a high throughput biodosimetry test system (REDI-Dx) suitable for testing of thousands of potential radiation victims following a mass scale nuclear event caused by detonation of a nuclear device or a nuclear accident, as ...
Full textLink to itemCite
Journal articlePLoS One · 2020
Allogeneic-HCT (allo-HCT), while potentially curative, can result in significant complications including graft versus host disease (GVHD). Prior studies suggest that metabolic syndrome may be one risk factor for GVHD. We hypothesized that hepatic steatosis ...
Full textLink to itemCite
Journal articleBest Pract Res Clin Haematol · December 2019
Allogeneic hematopoietic stem cell transplantation (HSCT) has the potential for providing a cure for several hematologic malignancies. Although in most circumstances, allogeneic HSCT is preceded by disease-directed or cytoreductive therapy, it is unclear i ...
Full textLink to itemCite
Journal articleScience · November 29, 2019
Disruption of intestinal microbial communities appears to underlie many human illnesses, but the mechanisms that promote this dysbiosis and its adverse consequences are poorly understood. In patients who received allogeneic hematopoietic cell transplantati ...
Full textLink to itemCite
Journal articleBlood · November 7, 2019
Burkitt lymphoma (BL) is an aggressive, MYC-driven lymphoma comprising 3 distinct clinical subtypes: sporadic BLs that occur worldwide, endemic BLs that occur predominantly in sub-Saharan Africa, and immunodeficiency-associated BLs that occur primarily in ...
Full textLink to itemCite
Journal articleTranspl Infect Dis · October 2019
BACKGROUND: Post-transplant lymphoproliferative disorders (PTLD) are associated with significant morbidity and mortality following allogeneic hematopoietic cell transplant (alloHCT). Although most PTLD is EBV-positive (EBVpos ), EBV-negative (EBVneg ) PTLD ...
Full textLink to itemCite
Journal articleClinical infectious diseases : an official publication of the Infectious Diseases Society of America · October 2019
BackgroundWe examined the impact of vancomycin-resistant Enterococcus (VRE) bloodstream infection (BSI) on outcomes of allogeneic hematopoietic cell transplantation (HCT) utilizing the Center for International Blood and Marrow Transplant Research ...
Full textCite
Journal articleStem Cell Reports · July 9, 2019
Hematopoietic stem and progenitor cells (HSPCs) depend on regulatory cytokines from the marrow microenvironment. From an unbiased cytokine screen of murine marrow supernatants, we identified C-C motif chemokine ligand 5 (CCL5) as an endothelial cell-secret ...
Full textLink to itemCite
Journal articleJAMA Dermatol · July 1, 2019
IMPORTANCE: Cutaneous chronic graft-vs-host disease (cGVHD) is common after allogeneic hematopoietic stem cell transplant and is often associated with poor patient outcomes. A reliable and practical method for assessing disease severity and response to the ...
Full textLink to itemCite
Journal articleNat Commun · June 4, 2019
Tumor-associated myeloid cells regulate tumor growth and metastasis, and their accumulation is a negative prognostic factor for breast cancer. Here we find calcium/calmodulin-dependent kinase kinase (CaMKK2) to be highly expressed within intratumoral myelo ...
Full textLink to itemCite
Journal articleInt J Radiat Oncol Biol Phys · June 1, 2019
PURPOSE: Extracellular vesicles (EVs) are shed vesicles that bear a combination of nucleic acids and proteins. EVs are becoming recognized as a mode of cell-to-cell communication. Because hematopoietic stem cells reside in proximity to endothelial cells (E ...
Full textLink to itemCite
Journal articleCancer Lett · January 2019
Multiple myeloma remains an incurable disease, and continued efforts are required to develop novel agents and novel drug combinations with more effective anti-myeloma activity. Here, we show that the pan-PIM kinase inhibitors SGI1776 and CX6258 exhibit sig ...
Full textLink to itemCite
Journal articlePLoS One · 2019
While exposure to radiation can be lifesaving in certain settings, it can also potentially result in long-lasting adverse effects, particularly to hematopoietic and immune cells. This study investigated hematopoietic recovery and immune function in rhesus ...
Full textLink to itemCite
Journal articleFront Immunol · 2019
Data from both animal models and humans have demonstrated that effector memory T cells (TEM) and central memory T cells (TCM) from unprimed donors have decreased ability to induce graft-vs-host disease (GVHD). Allospecific TEM from primed donors do not med ...
Full textLink to itemCite
Journal articleInt J Nanomedicine · 2019
Aim: To quantitatively and sensitively investigate the biodistribution of immune cells after systemic administration. Methods: Immune cells were loaded with plasmonic gold nanostars (GNS) tracking probes. Inductively coupled plasma mass spectrometry (ICP-M ...
Full textLink to itemCite
Journal articleCurrent Stem Cell Reports · December 1, 2018
Purpose of Review: Pharmacologic immunosuppression is the mainstay of treatment for GVHD, but there is a crucial need for new therapeutic approaches. Our review focuses on the preclinical and clinical evidence supporting immune regulatory cell infusions, a ...
Full textCite
Journal articleJCI Insight · October 4, 2018
Graft-versus-host disease (GVHD) is a major complication of hematopoietic stem cell transplantation (HCT). The tyrosine kinase SYK contributes to both acute and chronic GVHD development, making it an attractive target for GVHD prevention. Entospletinib (EN ...
Full textLink to itemCite
Journal articleJ Glob Oncol · September 2018
PURPOSE: The majority of new diagnoses of pediatric cancer are made in resource-poor countries, where survival rates range from 5% to 25% compared with 80% in high-resource countries. Multiple factors, including diagnostic and treatment capacities and comp ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · August 2018
Hematologic malignancies are characterized by genetic heterogeneity, making classic gene therapy with a goal of correcting 1 genetic defect ineffective in many of these diseases. Despite initial tribulations, gene therapy, as a field, has grown by leaps an ...
Full textLink to itemCite
Journal articleOpen Forum Infect Dis · June 2018
BACKGROUND: Rates and risk factors for recurrent enterococcal bloodstream infection (R-EBSI) and whether the same genetic lineage causes index EBSI and R-EBSI are unknown in patients with acute leukemia (AL) receiving chemotherapy. METHODS: Ninety-two AL p ...
Full textOpen AccessLink to itemCite
Journal articleBiol Blood Marrow Transplant · April 2018
Gastrointestinal (GI) complications including graft-versus-host disease (GVHD) are a major cause of morbidity and mortality in allogenic stem transplant recipients. Although several studies have previously looked into the acute GI complications, fewer smal ...
Full textLink to itemCite
Journal articleJMIR Mhealth Uhealth · March 19, 2018
BACKGROUND: Pain is a challenge for patients following hematopoietic stem cell transplantation (HCT). OBJECTIVE: This study aimed to develop and test the feasibility, acceptability, and initial efficacy of a Web-based mobile pain coping skills training (mP ...
Full textLink to itemCite
Journal articleJ Hematol Oncol · February 27, 2018
BACKGROUND: Although current chemotherapy using bortezomib (Velcade) against multiple myeloma in adults has achieved significant responses and even remission, a majority of patients will develop acquired resistance to bortezomib. Increased thioredoxin leve ...
Full textLink to itemCite
Journal articleStem Cells · February 2018
Hematopoietic regeneration following chemotherapy may be distinct from regeneration following radiation. While we have shown that epidermal growth factor (EGF) accelerates regeneration following radiation, its role following chemotherapy is currently unkno ...
Full textLink to itemCite
Journal articleExpert Rev Clin Pharmacol · February 2018
Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is an unpredictable condition associated with endothelial-cell damage due to conditioning for hematopoietic stem-cell transplantation (HSCT) or chemotherapy without HSCT. Mortality in ...
Full textLink to itemCite
Journal articleJAMA Oncol · January 1, 2018
IMPORTANCE: The outcome of older patients with acute myeloid leukemia (AML) remains unsatisfactory. Recent studies have shown that HLA-mismatched microtransplant could improve outcomes in such patients. OBJECTIVE: To evaluate outcomes in different age grou ...
Full textLink to itemCite
Journal articleBone Marrow Transplant · January 2018
Single-agent high-dose melphalan (HDM, 200 mg/m2) has been the most commonly used conditioning regimen prior to autologous stem cell transplant, since its introduction in 1992. We used a more aggressive alkylator-based conditioning regimen in an attempt to ...
Full textLink to itemCite
Journal articleHematol Oncol · December 2017
We retrospectively studied 340 fit patients with multiple myeloma (MM) who underwent autologous stem cell transplantation (ASCT). We hypothesized that progression-free survival (PFS) of older patients was non-inferior to that of younger patients after ASCT ...
Full textLink to itemCite
Journal articleHematol Oncol Stem Cell Ther · December 2017
Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (AHSCT) and the major cause of nonrelapse morbidity and mortality of AHSCT. In AHSCT, donor T cells facilitate hematopoietic stem cell (HSC) engr ...
Full textLink to itemCite
Journal articleBlood · November 9, 2017
B-cell receptor (BCR)-activated B cells contribute to pathogenesis in chronic graft-versus-host disease (cGVHD), a condition manifested by both B-cell autoreactivity and immune deficiency. We hypothesized that constitutive BCR activation precluded function ...
Full textLink to itemCite
Journal articleStem cell research & therapy · November 2017
BackgroundRadiation exposure poses a significant threat to public health. Hematopoietic injury is one of the major manifestations of acute radiation sickness. Protection and/or mitigation of hematopoietic stem cells (HSCs) from radiation injury is ...
Full textCite
Journal articleCell Death Dis · October 5, 2017
Hematopoietic stem and progenitor cells (HSPCs) are predominantly quiescent in adults, but proliferate in response to bone marrow (BM) injury. Here, we show that deletion of Ca2+/calmodulin (CaM)-dependent protein kinase kinase 2 (CaMKK2) promotes HSPC reg ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · July 2017
Delayed hematopoietic recovery contributes to increased infection risk following umbilical cord blood (UCB) transplantation. In a Phase 1 study, adult recipients of UCB stem cells cultured ex vivo for 3 weeks with nicotinamide (NiCord) had earlier median n ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · May 2017
Aggressive NK cell leukemia (ANKL) is an exceedingly rare form of leukemia and carries a poor prognosis, with a median survival of only 2 months. Using the Center for International Blood and Marrow Transplant Research database, we evaluated outcomes of all ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · February 2017
Comprehensive recommendations for maintenance therapy after autologous stem cell transplantation (ASCT) for patients with multiple myeloma (MM) have yet to be defined. Bortezomib has been utilized as maintenance therapy after ASCT, but data attesting to th ...
Full textLink to itemCite
Journal articleBone Marrow Transplant · February 2017
Cognitive problems are a significant, persistent concern for patients undergoing hematopoietic stem cell transplant (HSCT). Sleep is important for many cognitive tasks; however, the relationship between sleep and cognitive problems for HSCT patients is unk ...
Full textLink to itemCite
Journal articleNat Med · January 2017
The role of osteolineage cells in regulating hematopoietic stem cell (HSC) regeneration following myelosuppression is not well understood. Here we show that deletion of the pro-apoptotic genes Bak and Bax in osterix (Osx, also known as Sp7 transcription fa ...
Full textLink to itemCite
Journal articleCell Rep · November 1, 2016
Imprinted genes are differentially expressed by adult stem cells, but their functions in regulating adult stem cell fate are incompletely understood. Here we show that growth factor receptor-bound protein 10 (Grb10), an imprinted gene, regulates hematopoie ...
Full textOpen AccessLink to itemCite
Journal articleClin Infect Dis · October 15, 2016
BACKGROUND: Respiratory viral infections (RVIs) are frequent complications of hematopoietic stem cell transplant (HSCT). Surgical masks are a simple and inexpensive intervention that may reduce nosocomial spread. METHODS: In this prospective single-center ...
Full textLink to itemCite
Journal articleJ Hematol Oncol · August 17, 2016
BACKGROUND: The binding of CXCR4 with its ligand (stromal-derived factor-1) maintains hematopoietic stem/progenitor cells (HSPCs) in a quiescent state. We hypothesized that blocking CXCR4/SDF-1 interaction after hematopoietic stem cell transplantation (HSC ...
Full textOpen AccessLink to itemCite
Journal articleDig Dis Sci · March 2016
BACKGROUND: Graft-versus-host disease (GVHD) complicates half of hematopoietic stem cell transplants (HCT), and the gastrointestinal tract is commonly affected. Endoscopic biopsies have a key role in the diagnosis. The optimal procedure(s) to perform and s ...
Full textLink to itemCite
Journal articlePediatr Blood Cancer · December 2015
BACKGROUND: X-linked hyper-IgM syndrome (X-HIGM) due to mutations in the gene encoding CD40 ligand results in failure of Ig class switching and an increased propensity for recurrent sinopulmonary and other infections, and thus decreased life expectancy. Al ...
Full textLink to itemCite
Journal articleJ Immunol · November 1, 2015
Dendritic epidermal T cells (DETCs) are generated exclusively in the fetal thymus and maintained in the skin epithelium throughout postnatal life of the mouse. DETCs have restricted antigenic specificity as a result of their exclusive usage of a canonical ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · October 2015
Combinations of cyclosporine (CSP) with methotrexate (MTX) have been widely used for immunosuppression after allogeneic transplantation for acquired aplastic anemia. We compared outcomes with tacrolimus (TAC)+MTX versus CSP+MTX after transplantation from H ...
Full textLink to itemCite
Journal articleBlood · June 25, 2015
Novel therapies for chronic graft-versus-host disease (cGVHD) are needed. Aberrant B-cell activation has been demonstrated in mice and humans with cGVHD. Having previously found that human cGVHD B cells are activated and primed for survival, we sought to f ...
Full textLink to itemCite
Journal articleJ Clin Apher · June 2015
High-dose cyclophosphamide (Cy) is frequently employed for peripheral blood mobilization of hematopoietic stem cells before high-dose chemotherapy with autologous stem cell transplantation (ASCT) in multiple myeloma (MM). The benefit of mobilization with C ...
Full textLink to itemCite
Journal articleInt J Radiat Biol · June 2015
PURPOSE: The threat of radiation exposure requires a mechanistic understanding of radiation-induced immune injury and recovery. The study objective was to evaluate responses to ionizing radiation in ovariectomized (surgically post-menopausal) female cynomo ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · February 2015
Although transplant practices have changed over the last decades, no information is available on trends in incidence and outcome of chronic graft-versus-host disease (cGVHD) over time. This study used the central database of the Center for International Bl ...
Full textLink to itemCite
Journal articleJ Clin Invest · January 2015
Hematopoietic stem cell (HSC) function is regulated by activation of receptor tyrosine kinases (RTKs). Receptor protein tyrosine phosphatases (PTPs) counterbalance RTK signaling; however, the functions of receptor PTPs in HSCs remain incompletely understoo ...
Full textOpen AccessLink to itemCite
Journal articleJ Clin Invest · November 2014
Hematopoietic stem cells (HSCs) are highly susceptible to ionizing radiation-mediated death via induction of ROS, DNA double-strand breaks, and apoptotic pathways. The development of therapeutics capable of mitigating ionizing radiation-induced hematopoiet ...
Full textLink to itemCite
Journal articleMed Phys · August 2014
PURPOSE: For orthovoltage x-ray irradiators, the tube voltage is one of the most fundamental system parameters as this directly relates to the dosimetry in radiation biology studies; however, to the best of our knowledge, there is no commercial portable qu ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · July 2014
Non-Hodgkin lymphoma (NHL) disproportionately affects older patients, who do not often undergo allogeneic hematopoietic cell transplantation (HCT). We analyzed Center for International Blood and Marrow Transplant Research data on 1248 patients age ≥40 year ...
Full textLink to itemCite
Journal articleJ Clin Invest · July 2014
BACKGROUND: Delayed hematopoietic recovery is a major drawback of umbilical cord blood (UCB) transplantation. Transplantation of ex vivo-expanded UCB shortens time to hematopoietic recovery, but long-term, robust engraftment by the expanded unit has yet to ...
Full textOpen AccessLink to itemCite
Journal articleBlood · June 26, 2014
Sinusoidal obstruction syndrome (SOS), previously called veno-occlusive disease (VOD) can be a difficult problem after hematopoietic cell transplantation (HCT). The overall incidence has changed since the early days of allogeneic HCT. Prophylaxis and treat ...
Full textLink to itemCite
Journal articleGenes Dev · May 1, 2014
Accidental or deliberate ionizing radiation exposure can be fatal due to widespread hematopoietic destruction. However, little is known about either the course of injury or the molecular pathways that regulate the subsequent regenerative response. Here we ...
Full textLink to itemCite
Journal articleRadiat Res · May 2014
Exposure to a nuclear accident or radiological attack can cause death from acute radiation syndrome (ARS), which results from radiation injury to vital organs such as the hematopoietic system. However, the U.S. Food and Drug Administration (FDA) has not ap ...
Full textLink to itemCite
Journal articleBlood · March 27, 2014
Although B cells have emerged as important contributors to chronic graft-versus-host-disease (cGVHD) pathogenesis, the mechanisms responsible for their sustained activation remain unknown. We previously showed that patients with cGVHD have significantly in ...
Full textLink to itemCite
Journal articleMed Phys · March 2014
PURPOSE: Accurate dosimetry is essential when irradiating mice to ensure that functional and molecular endpoints are well understood for the radiation dose delivered. Conventional methods of prescribing dose in mice involve the use of a single dose rate me ...
Full textLink to itemCite
Journal articleExpert Opin Investig Drugs · March 2014
INTRODUCTION: The Wilms tumor 1 (WT1) gene was originally identified as a tumor suppressor gene that, when mutated, would lead to the development of pediatric renal tumors. More recently, it has been determined that WT1 is overexpressed in 90% of patients ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · February 2014
We present a comparative study on 124 patients with hematologic malignancies who had undergone reduced-intensity conditioning and then received a transplant from an HLA-matched related (MRD), an HLA-matched unrelated (MUD), or an HLA-haploidentical related ...
Full textLink to itemCite
Journal articlePLoS One · 2014
Terrorism using radiological dirty bombs or improvised nuclear devices is recognized as a major threat to both public health and national security. In the event of a radiological or nuclear disaster, rapid and accurate biodosimetry of thousands of potentia ...
Full textOpen AccessLink to itemCite
Journal articleFront Oncol · 2014
The growing burden of non-communicable diseases including cancer in low- and lower-middle income countries (LMICs) and in geographic-access limited settings within resource-rich countries requires effective and sustainable solutions. The International Canc ...
Full textLink to itemCite
Journal articleJ Leukoc Biol · December 2013
Chemokine receptor interactions coordinate leukocyte migration in inflammation. Chemokine receptors are GPCRs that when activated, are phosphorylated by GRKs to turn off G protein-mediated signaling yet recruit additional signaling machinery. Recently, GRK ...
Full textLink to itemCite
Journal articleBlood · November 7, 2013
Acute graft-versus-host disease (aGVHD) is the leading cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). Approximately 35% to 50% of HCT recipients develop aGVHD; however, there are no validated diagnostic and pred ...
Full textLink to itemCite
Journal articleBone Marrow Transplantation · November 1, 2013
Chemotherapy plus G-CSF (C+G) and G-CSF alone are two of the most common methods used to mobilize CD34 + cells for autologous hematopoietic SCT (AHSCT). In order to compare and determine the real-world outcomes and costs of these strategies, we performed a ...
Full textCite
Journal articleBone Marrow Transplant · November 2013
Chemotherapy plus G-CSF (C+G) and G-CSF alone are two of the most common methods used to mobilize CD34(+) cells for autologous hematopoietic SCT (AHSCT). In order to compare and determine the real-world outcomes and costs of these strategies, we performed ...
Full textOpen AccessLink to itemCite
Journal articleBest Pract Res Clin Haematol · September 2013
Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplant (AHSCT) associated with significant morbidity and mortality. This review focuses on the pathophysiology, prevention, and treatment of acute GVHD. Spec ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · September 2013
Adequate hematopoietic stem cell (HSC) mobilization and collection is required prior to proceeding with high dose chemotherapy and autologous hematopoietic stem cell transplant. Cytokines such as G-CSF, GM-CSF, and peg-filgrastim, alone or in combination w ...
Full textLink to itemCite
Journal articleBone Marrow Transplant · July 2013
High fevers and/or rashes prior to neutrophil engraftment are frequently observed after umbilical cord blood (UCB) transplantation, and the condition is referred to as pre-engraftment syndrome (PES). Few studies have evaluated the risk factors for and trea ...
Full textOpen AccessLink to itemCite
Journal articleJ Clin Invest · June 2013
There is a ying/yang to most biological therapies, and the balance of efficacy versus toxicity is delicate and sometimes difficult to achieve in favor of the patients. When the therapeutic window is wide, these therapies can be used in the majority of pati ...
Full textLink to itemCite
Journal articleInt J Radiat Oncol Biol Phys · March 15, 2013
PURPOSE: To investigate whether and how insulin-like growth factor 1 (IGF-1) mitigates hematopoietic toxicity after total body irradiation. METHODS AND MATERIALS: BALB/c mice were irradiated with a lethal dose of radiation (7.5 Gy) and treated with IGF-1 a ...
Full textLink to itemCite
Journal articleNat Med · March 2013
The mechanisms that regulate hematopoietic stem cell (HSC) regeneration after myelosuppressive injury are not well understood. We identified epidermal growth factor (EGF) to be highly enriched in the bone marrow serum of mice bearing deletion of Bak and Ba ...
Full textOpen AccessLink to itemCite
Journal articleCancer Invest · March 2013
PURPOSE: This Phase I study assessed the feasibility of concomitant arsenic trioxide (ATO), ascorbic acid (AA), and bortezomib (Velcadeâ„¢) (AAV) for patients with relapsed/refractory multiple myeloma. EXPERIMENTAL DESIGN: ATO (0.25 mg/kg) and AA (1 g) were ...
Full textLink to itemCite
Journal articleStem Cells · February 2013
Hematopoietic stem cells (HSCs) reside in proximity to bone marrow endothelial cells (BM ECs) and maintenance of the HSC pool is dependent upon EC-mediated c-kit signaling. Here, we used genetic models to determine whether radioprotection of BM ECs could f ...
Full textLink to itemCite
Journal articleBlood · January 31, 2013
UNLABELLED: Cell dose is a major limitation for umbilical cord blood (UCB) transplantation because units containing a minimum of 2.5 x 10(7) total nucleated cells (TNC)/kilogram patient body weight are frequently not available. The transplantation of 2 par ...
Full textLink to itemCite
Journal articlePLoS One · 2013
Two-photon microscopy has enabled the study of individual cell behavior in live animals. Many organs and tissues cannot be studied, especially longitudinally, because they are located too deep, behind bony structures or too close to the lung and heart. Her ...
Full textLink to itemCite
Journal articleStem Cells Transl Med · January 2013
Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplant (AHSCT) associated with significant morbidity and mortality. This review focuses on the pathophysiology, clinical features, prevention, and treatment ...
Full textLink to itemCite
Journal articleBiosecur Bioterror · December 2012
This article summarizes major points from a newly released guide published online by the Office of the Assistant Secretary for Preparedness and Response (ASPR). The article reviews basic principles about radiation and its measurement, short-term and long-t ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · November 2012
Immunologic reconstitution after allogeneic hematopoietic cell transplantation is a critical component of successful outcome. Umbilical cord blood (UCB) transplantation in adult recipients is associated with slow and often inadequate immune recovery. We ch ...
Full textLink to itemCite
Journal articleCell Rep · October 25, 2012
The mechanisms through which the bone marrow (BM) microenvironment regulates hematopoietic stem cell (HSC) fate remain incompletely understood. We examined the role of the heparin-binding growth factor pleiotrophin (PTN) in regulating HSC function in the n ...
Full textLink to itemCite
Journal articleBlood · October 4, 2012
Graft-versus-host disease (GVHD) remains the most common cause of nonrelapse-related morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although T-cell depletion and intensive immunosuppression are effective in th ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · October 2012
We studied whether allospecific CD4(+) effector memory T cells (T(EM)) could induce graft-versus-host disease (GVHD) using a novel GVHD model induced solely by CD4(+) T cell receptor transgenic TEa cells. Allospecific T(EM) generated in a lymphopenic host ...
Full textLink to itemCite
Journal articleBone Marrow Transplant · August 2012
Plerixafor, given on day 4 of G-CSF treatment is more effective than G-CSF alone in mobilizing hematopoietic progenitor cells. We tested a strategy of preemptive plerixafor use following assessment of the peak mobilization response to 5 days of G-CSF. Pati ...
Full textLink to itemCite
Journal articleBone Marrow Transplant · June 2012
The impact of activating KIR (aKIR) and inhibitory KIR (iKIR) on OS, relapse-related mortality (RRM) and acute GVHD (aGVHD) was prospectively studied in 84 adults with high-risk hematologic malignancies receiving reduced intensity conditioning (RIC) T-cell ...
Full textLink to itemCite
Journal articleBone Marrow Transplant · May 2012
Primary graft failure after allogeneic hematopoietic cell transplantation is a life-threatening complication. A shortened conditioning regimen may reduce the risk of infection and increase the chance of survival. Here, we report the outcome of 11 patients ...
Full textLink to itemCite
Journal articleBlood · February 2, 2012
Selective depletion of the alloreactiveT cells causing graft-versus-host disease (GVHD) without loss of the graft-versus-leukemia (GVL) effect is the holy grail of hematopoietic cell transplantation (HCT). In this issue of Blood, He et al demonstrate that ...
Full textCite
Journal articleBlood · January 5, 2012
Risk factors for acute GVHD (AGVHD), overall survival, and transplant-related mortality were evaluated in adults receiving allogeneic hematopoietic cell transplants (1999-2005) from HLA-identical sibling donors (SDs; n = 3191) or unrelated donors (URDs; n ...
Full textLink to itemCite
Journal articleAdv Hematol · 2012
Although multiple myeloma remains incurable outside of allogeneic hematopoietic stem cell transplantation, novel agents made available only in the last few decades have nonetheless tremendously improved the landscape of myeloma treatment. Lenalidomide, of ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · January 2012
Bone marrow transplant (BMT) teams do not generally consider themselves to be emergency responders. But the bone marrow is the most radiosensitive organ in the body, and early changes in peripheral blood counts remain the best indicator of major total-body ...
Full textLink to itemCite
Journal articleTransfusion · January 2012
BACKGROUND: We analyzed neonatal factors that could affect hematopoietic variables of cord blood (CB) donated from Korean neonates. STUDY DESIGN AND METHODS: The numbers of total nucleated cells (TNCs), CD34+ cells, and CD34+ cells/TNCs of CB in neonates w ...
Full textLink to itemCite
Journal articleInt J Radiat Oncol Biol Phys · November 1, 2011
PURPOSE: To assess factors associated with severe pulmonary toxicity after myeloablative conditioning using total body irradiation (TBI) followed by allogeneic stem cell transplantation. METHODS AND MATERIALS: A total of 101 adult patients who underwent TB ...
Full textLink to itemCite
Journal articleDisaster Med Public Health Prep · October 2011
OBJECTIVES: The World Health Organization convened a panel of experts to rank the evidence for medical countermeasures for management of acute radiation syndrome (ARS) in a hypothetical scenario involving the hospitalization of 100 to 200 victims. The goal ...
Full textLink to itemCite
Journal articleDisaster Med Public Health Prep · October 2011
OBJECTIVE: Hematopoietic syndrome (HS) is a clinical diagnosis assigned to people who present with ≥ 1 new-onset cytopenias in the setting of acute radiation exposure. The World Health Organization convened a panel of experts to evaluate the evidence and d ...
Full textLink to itemCite
Journal articleInt J Radiat Biol · August 2011
PURPOSE: To present previously unavailable data on the use of stem cell administration to aid recovery of victims of the Chernobyl disaster. On 26 April 1986, an accident at Unit 4 of the Chernobyl Nuclear Power Plant took place during the planned test of ...
Full textLink to itemCite
Journal articleInt J Radiat Biol · August 2011
PURPOSE: Radiation and wound combined injury represents a major clinical challenge because of the synergistic interactions that lead to higher morbidity and mortality than either insult would produce singly. The purpose of this study was to develop a mouse ...
Full textLink to itemCite
Journal articleInt J Radiat Biol · August 2011
PURPOSE: To describe the history, composition, and activities of the Radiation Injury Treatment Network (RITN). The Radiation Injury Treatment Network® is a cooperative effort of the National Marrow Donor Program and the American Society for Blood and Marr ...
Full textLink to itemCite
Journal articleBone Marrow Transplant · June 2011
Positron emission tomography (PET) in conjunction with computed tomography is a frequently used modality for staging patients with lymphoma. Utility of PET-computed tomography before or early following auto-SCT has not been as rigorously evaluated. We retr ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · June 2011
High treatment-related mortality (TRM) and high graft failure rate are serious concerns in HLA-mismatched umbilical cord blood (UCB) transplantation with myeloablative conditioning. We conducted a prospective trial of dual UCB transplantation using modifie ...
Full textLink to itemCite
Journal articleImmunol Res · April 2011
Allogeneic hematopoietic cell transplantation has developed into a most successful form of immunotherapy for hematologic malignancies in the past 50Â years. However, its effectiveness and wider applications have been greatly limited by the development of gr ...
Full textLink to itemCite
Journal articleInt J Radiat Oncol Biol Phys · March 15, 2011
PURPOSE: To describe renal shielding techniques and dosimetry in delivering total body irradiation (TBI) to patients with severe systemic sclerosis (SSc) enrolled in a hematopoietic stem cell transplant protocol. METHODS AND MATERIALS: The Scleroderma: Cyc ...
Full textLink to itemCite
Journal articleDisaster Med Public Health Prep · March 2011
A 10-kiloton (kT) nuclear detonation within a US city could expose hundreds of thousands of people to radiation. The Scarce Resources for a Nuclear Detonation Project was undertaken to guide community planning and response in the aftermath of a nuclear det ...
Full textLink to itemCite
Journal articleExpert Rev Hematol · February 2011
Iron overload is frequently observed in patients with hematologic diseases before and after allogeneic stem-cell transplantation because they usually receive multiple red blood cell transfusions. Elevated pretransplant serum ferritin levels, which are wide ...
Full textLink to itemCite
Journal articleCancer Invest · January 2011
INTRODUCTION: High relapse rates and infections remain primary causes of failure in nonmyeloablative transplantation. Interleukin-2 (IL-2) may stimulate the immune system and improve outcomes. The primary objective of this pilot study was to evaluate the f ...
Full textLink to itemCite
Journal articleBlood · December 16, 2010
Two critical concerns in clinical cord blood transplantation are the initial time to engraftment and the subsequent restoration of immune function. These studies measured the impact of progenitor cell dose on both the pace and strength of hematopoietic rec ...
Full textLink to itemCite
Journal articleCellular Therapy and Transplantation · December 1, 2010
As the outcomes of umbilical cord blood transplantation improve, the risk versus benefit considerations with respect to treatment of non-malignant disorders must be reassessed. Recent data would suggest that the outcome of umbilical cord blood transplantat ...
Full textCite
Journal articleBiol Blood Marrow Transplant · October 2010
Hematologists/oncologists would provide essential care for victims of a catastrophic radiation incident, such as the detonation of an improvised nuclear device (IND). The US Radiation Injury Treatment Network (RITN) is a voluntary consortium of 37 academic ...
Full textLink to itemCite
Journal articleCurr Oncol Rep · September 2010
Hematopoietic stem cell transplantation from human leukocyte antigen (HLA)-haploidentical family members offers a potential cure for patients in need of allogeneic immunotherapy who have no immediate access to an HLA-matched donor. The use of ex vivo T-cel ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · August 2010
Infusing natural killer (NK) cells following transplantation may allow less infections and relapse with little risk of acute graft-versus-host disease (aGVHD). We delivered 51 total NK cell-enriched donor lymphocyte infusions (DLIs) to 30 patients followin ...
Full textLink to itemCite
Journal articlePLoS One · July 12, 2010
In the event of a terrorist-mediated attack in the United States using radiological or improvised nuclear weapons, it is expected that hundreds of thousands of people could be exposed to life-threatening levels of ionizing radiation. We have recently shown ...
Full textOpen AccessLink to itemCite
Journal articleCancer Invest · July 2010
We present a study of the prevalence of genetic polymorphisms and expression of genes encoding the drug-resistance proteins glutathione S-transferases (GSTs) in order to gain insights into the pattern of failure evident in mantle cell lymphoma. We note a h ...
Full textLink to itemCite
Journal articleLancet Oncol · July 2010
BACKGROUND: Umbilical-cord blood (UCB) is increasingly considered as an alternative to peripheral blood progenitor cells (PBPCs) or bone marrow, especially when an HLA-matched adult unrelated donor is not available. We aimed to determine the optimal role o ...
Full textLink to itemCite
Journal articlePLoS One · June 28, 2010
The interaction between stromal cell-derived factor-1 (SDF-1) with CXCR4 chemokine receptors plays an important role in hematopoiesis following hematopoietic stem cell transplantation. We examined the efficacy of post transplant administration of a specifi ...
Full textOpen AccessLink to itemCite
Journal articlePLoS One · June 16, 2010
Medications that can mitigate against radiation injury are limited. In this study, we investigated the ability of recombinant human growth hormone (rhGH) to mitigate against radiation injury in mice and nonhuman primates. BALB/c mice were irradiated with 7 ...
Full textOpen AccessLink to itemCite
Journal articleBest Pract Res Clin Haematol · June 2010
Allogeneic umbilical cord blood (UCB) transplantation is an established alternative to unrelated bone marrow or peripheral blood transplantation for treatment of high-risk hematologic disorders. There is growing evidence that non-myeloablative bone marrow ...
Full textLink to itemCite
Journal articleNat Med · April 2010
Hematopoietic stem cell (HSC) self-renewal is regulated by both intrinsic and extrinsic signals. Although some of the pathways that regulate HSC self-renewal have been uncovered, it remains largely unknown whether these pathways can be triggered by deliver ...
Full textLink to itemCite
Journal articleStem Cells · March 31, 2010
Hematopoietic stem cells (HSCs) are enriched for aldehyde dehydrogenase (ALDH) activity and ALDH is a selectable marker for human HSCs. However, the function of ALDH in HSC biology is not well understood. We sought to determine the function of ALDH in regu ...
Full textLink to itemCite
Journal articleF1000 Med Rep · February 11, 2010
Umbilical cord blood is an acceptable source of hematopoietic stem cells for patients with malignant diseases but has limitations in its use. In this review, we will discuss these limitations and the recent advances in cord blood transplants that may enabl ...
Full textLink to itemCite
Journal articleBone Marrow Transplant · February 2010
Rapamycin (RAPA) is an immunosuppressive drug that prevents and treats graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplant (HCT). One possible mechanism for its efficacy is induction of tolerance, through increased number or enh ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · January 2010
The purpose of this study was to evaluate the efficacy and safety of short-course bortezomib, melphalan, prednisone (VMP) in previously untreated multiple myeloma as frontline therapy for transplant-ineligible patients and induction prior to autologous ste ...
Full textLink to itemCite
Journal articleDrugs · July 9, 2009
Graft-versus-host disease (GVHD) after allogeneic stem-cell transplantation causes significant morbidity and mortality. An important site of GVHD is the gastrointestinal (GI) tract because development of acute GI GVHD is prognostic of overall survival. The ...
Full textLink to itemCite
Journal articleCancer · July 1, 2009
BACKGROUND: Response and survival in 96 patients with secondary acute myeloid leukemia (sAML) who received aggressive induction chemotherapy was reviewed. METHODS: The median follow-up of survivors was 2.3 years. A total of 70 (73%) patients achieved a mor ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · July 2009
Currently, no agents are approved by the United States Food and Drug Administration (FDA) for either prevention or treatment of acute graft-versus-host disease (aGVHD). Formal precedents establishing a comparative basis for assessing the efficacy and safet ...
Full textLink to itemCite
Journal articleBlood · May 21, 2009
Tumor-specific T-cell tolerance represents one major mechanism of tumor-induced immune evasion. Myeloablative chemotherapy with stem cell transplantation may offer the best chance of achieving a state of minimal residual disease and, thus, minimize tumor-i ...
Full textLink to itemCite
Journal articleLeuk Lymphoma · May 2009
Non-cross resistant drugs given at high-dose intensity may maximise tumor cell kill leading to improved patient outcomes. We investigated the feasibility and efficacy of administering ifosfamide, carboplatin and etoposide +/- rituximab as sequential high-d ...
Full textLink to itemCite
Journal articleStem Cells · May 2009
The concern of the public regarding terrorist actions involving nuclear emergencies resulted in the reopening of the discussion regarding the best ways to cope with the inevitable health impairments. Medical experts from the US and from Europe considered i ...
Full textLink to itemCite
Journal articleClin Cancer Res · April 15, 2009
PURPOSE: Wilms' tumor protein (WT1) is overexpressed in most leukemias and many solid tumors and is a promising target for tumor immunotherapy. WT1 peptide-based cancer vaccines have been reported but have limited application due to HLA restriction of the ...
Full textLink to itemCite
Journal articleExpert Rev Hematol · April 2009
Umbilical cord blood transplantation is becoming an acceptable alternative source of hematopoietic stem cells for patients with malignant diseases. Cord blood differs from bone marrow and peripheral blood progenitors in its immune tolerance and kinetics of ...
Full textLink to itemCite
Journal articleBlood · February 26, 2009
Hematopoietic stem cells (HSCs) reside in association with bone marrow (BM) sinusoidal vessels in vivo, but the function of BM endothelial cells (ECs) in regulating hematopoiesis is unclear. We hypothesized that hematopoietic regeneration following injury ...
Full textLink to itemCite
Journal articleMol Endocrinol · February 2009
The retinoid X receptor (RXR) contributes to the regulation of diverse biological pathways via its role as a heterodimeric partner of several nuclear receptors. However, RXR has no established role in the regulation of hematopoietic stem cell (HSC) fate. I ...
Full textLink to itemCite
Journal articleBone Marrow Transplant · February 2009
We report the outcome of early donor lymphocyte infusions (DLIs) after T-cell depleted non-myeloablative transplantation using stem cells from HLA-matched or mismatched donors. Sixty-nine patients with high-risk hematologic malignancies received DLI follow ...
Full textLink to itemCite
Journal article · January 1, 2009
INTRODUCTION. Chronic graft versus host disease (GVHD) is the major complication in long-term survivors of an allogeneic hematopoietic stem cell transplant (HSCT): its detrimental effect on quality of life, especially when extensive or severe, together wit ...
Full textCite
Journal articleCurr Opin Hematol · November 2008
PURPOSE OF REVIEW: Unmanipulated or CD34 selected haplotype mismatched transplantation provides the benefits of hematopoietic stem cell transplant for nearly all patients who do not have a human leukocyte antigen fully matched sibling or who urgently need ...
Full textLink to itemCite
Journal articleBone Marrow Transplant · August 2008
Haploidentical hematopoietic stem cell transplantation (HSCT) provides an opportunity for nearly all patients to benefit from HCT when a HLA genotypically matched sibling is not available. Initial results with the use of mismatched allografts led to limite ...
Full textLink to itemCite
Journal articleBlood · June 15, 2008
Untoward events involving radioactive material, either accidental or intentional, are potentially devastating. Hematologists and oncologists are uniquely suited to help manage radiation victims, as myelosuppression is a frequent complication of radiation e ...
Full textLink to itemCite
Journal articleBlood · June 1, 2008
The anti-cytomegalovirus (CMV) activity and safety of oral maribavir in CMV-seropositive allogeneic stem-cell transplant recipients were evaluated in a randomized, double-blind, placebo-controlled, dose-ranging study. After engraftment, 111 patients were r ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · May 2008
The efficacy of once-daily intravenous busulfan with fludarabine as a preparative regimen for partially matched umbilical cord blood transplantation has not been formally studied. We randomized 10 adult patients with myeloid malignancies to receive either ...
Full textLink to itemCite
Journal articlePLoS One · April 2, 2008
BACKGROUND: Previous work has demonstrated the potential for peripheral blood (PB) gene expression profiling for the detection of disease or environmental exposures. METHODS AND FINDINGS: We have sought to determine the impact of several variables on the P ...
Full textOpen AccessLink to itemCite
Journal articleBest Pract Res Clin Haematol · March 2008
The molecular biology and pathophysiology underlying graft-versus-host disease (GvHD) remains an area of intensive research. Understanding normal and abnormal developments of both the innate and adaptive immune systems are beginning to provide understandin ...
Full textLink to itemCite
Journal articleHematology Am Soc Hematol Educ Program · 2008
Applying for a grant seems like an enormous challenge, sometimes akin to Sisyphus' task of rolling the boulder up the hill. In many ways, obtaining funding can be challenging, yet year after year, new investigators do obtain funding, even though there are ...
Full textLink to itemCite
Journal articleCytotherapy · 2008
BACKGROUND: Cytomegalovirus (CMV) infection and its treatment causes significant morbidity following allogeneic stem cell transplantation (SCT) for malignancies. We studied the phenotype, function and growth kinetics of CMV pp65 antigen (Ag)-specific T cel ...
Full textLink to itemCite
Journal articleBone Marrow Transplant · January 2008
Following initial graft rejection, a second attempt at allogeneic immunotherapy is often contemplated, but data on the success is limited. We therefore report on 11 patients with hematologic malignancies, renal cell cancer or marrow failure who underwent a ...
Full textLink to itemCite
Journal articleBlood Cells Mol Dis · 2008
Haploidentical hematopoietic stem cell transplantation (HSCT) provides an opportunity for patients to benefit from HCT when a human leukocyte antigen (HLA) genotypically matched sibling is not available. Initial results with the use of mismatched allograft ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · December 2007
End-organ damage is common in patients with sickle cell disease (SCD) thereby limiting the use of allogeneic stem cell transplantation (SCT). We report the outcome of 2 adult SCD patients, 1 with end-stage renal disease (ESRD), who underwent fludarabine-ba ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · November 2007
Haploidentical hematopoietic stem cell transplantation (HSCT) provides an opportunity for nearly all patients to benefit from HSCT when a human leukocyte antigen (HLA) genotypically matched sibling is not available. Initial results with the use of mismatch ...
Full textLink to itemCite
Journal articlePLoS Med · April 2007
BACKGROUND: The capacity to assess environmental inputs to biological phenotypes is limited by methods that can accurately and quantitatively measure these contributions. One such example can be seen in the context of exposure to ionizing radiation. METHOD ...
Full textOpen AccessLink to itemCite
Journal articleBlood · April 1, 2007
Several groups, including our own, have independently demonstrated that effector memory T cells from non-alloantigen-primed donors do not cause graft-versus-host disease (GVHD). In the current study, we further investigated whether this approach could be e ...
Full textLink to itemCite
Journal articleExp Hematol · April 2007
The potential risk of accidental and especially intentional radiation exposure in the form of a terrorist attack is growing. The dangers are potentially devastating. There is an urgent need for building a greater infrastructure for teaching and research in ...
Full textLink to itemCite
Journal articleBlood · March 15, 2007
Flk-1(+) endothelial progenitors contribute critically to the definitive onset of hematopoiesis during embryogenesis. Recent studies have suggested that adult sources of endothelial cells also possess hematopoietic activity. In this study, we sought to det ...
Full textLink to itemCite
Journal articleJ Clin Oncol · February 20, 2007
PURPOSE: Allogeneic transplantation is typically limited to younger patients having a matched donor. To allow a donor to be found for nearly all patients, we have used a nonmyeloablative conditioning regimen in conjunction with stem cells from a related do ...
Full textLink to itemCite
Journal articleBiology of Blood and Marrow Transplantation · January 1, 2007
Radiation or marrow toxic emergencies can lead to severe pancytopenia along with other multiorgan injury. Experience in managing severe myelosuppression suggests that hematology, oncology and transplantation physicians should participate in preparedness pl ...
Full textCite
Journal articleBone Marrow Transplant · January 2007
Regulatory T cells (Tregs) are a specialized subpopulation of T cells that act to suppress activation of other immune cells and thereby maintain immune system homeostasis, self-tolerance as well as control excessive response to foreign antigens. The mere c ...
Full textLink to itemCite
Journal articleArch Pathol Lab Med · October 2006
CONTEXT: Nonmyeloablative stem cell transplantation (NMSCT) is a mode of immunotherapy increasingly employed in treating hematologic, lymphoid, and solid tumors. Patients are monitored principally by molecular analysis of donor engraftment. OBJECTIVE: To d ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · September 2006
Diffuse alveolar hemorrhage (DAH) after allogeneic hematopoietic stem cell transplantation (HSCT) is often fatal. Standard therapy with high-dose corticosteroid is not always effective. There is paucity of data in the literature about other potentially use ...
Full textLink to itemCite
Journal articleProc Natl Acad Sci U S A · August 1, 2006
Aldehyde dehydrogenase (ALDH) is an enzyme that is expressed in the liver and is required for the conversion of retinol (vitamin A) to retinoic acids. ALDH is also highly enriched in hematopoietic stem cells (HSCs) and is considered a selectable marker of ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · June 2006
Evaluation and management of victims of exposure to myelosuppressive radiation in a military, terrorist, or accidental event is challenging. The hematopoietic syndrome with marrow suppression and pancytopenia follows intermediate intensity radiation exposu ...
Full textLink to itemCite
Journal articleStem Cells · May 2006
Recent progress has been made in the identification of the osteoblastic cellular niche for hematopoietic stem cells (HSCs) within the bone marrow (BM). Attempts to identify the soluble factors that regulate HSC self-renewal have been less successful. We ha ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · May 2006
The risk of terrorism with nuclear or radiologic weapons is considered to be high over the coming decade. Ionizing radiation can cause a spectrum of hematologic toxicities, from mild myelosuppression to myeloablation and death. However, the potential regen ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · March 2006
T-cell receptor variable beta chain (TCRBV) repertoire spectratyping involves the estimation of CDR3 length distributions for monitoring T-cell receptor diversity and has proven useful for analyses of immune reconstitution and T-cell clonal expansions in g ...
Full textLink to itemCite
Journal articleTranspl Infect Dis · March 2006
Allogeneic hematopoietic stem cell transplant (HSCT) recipients are at increased risk for invasive fungal infections (IFIs) over prolonged periods of time. Aerosolized amphotericin B lipid complex (ABLC) has shown promise in lung transplant recipients as a ...
Full textLink to itemCite
Journal articleSemin Hematol · January 2006
Acute graft-versus-host disease (GVHD) remains a major obstacle to successful allogeneic hematopoietic stem cell transplantation (HSCT). The ability to prevent GVHD--the application of successful prophylaxis--is crucial as treatment when prophylaxis fails ...
Full textLink to itemCite
Journal articleJ Clin Invest · December 2005
In this study, we investigated whether elimination of CD4+/CD25+ Tregs using the recombinant IL-2 diphtheria toxin conjugate DAB(389)IL-2 (also known as denileukin diftitox and ONTAK) is capable of enhancing the immunostimulatory efficacy of tumor RNA-tran ...
Full textLink to itemCite
Journal articleBlood · July 1, 2005
A broad range of hematopoietic stem cells and progenitors reside within a fraction of umbilical cord blood (UCB) that exhibits low light scatter properties (SSC(lo)) and high expression of aldehyde dehydrogenase (ALDH(br)). Many SSC(lo) ALDH(br) cells coex ...
Full textLink to itemCite
Journal articleBlood Rev · July 2005
Allogeneic transplant offers a curative option for selected hematological malignancies and improved disease free survival in those where cure is not possible. For patients in these categories, Graft-versus-host disease (GVHD) occurs often and is a signific ...
Full textLink to itemCite
Journal articleAntimicrob Agents Chemother · April 2005
In this dose escalation study, 74 adult cancer patients undergoing bone marrow or peripheral blood stem cell transplantation received fluconazole (400 mg/day) and either normal saline (control) (12 subjects) or micafungin (12.5 to 200 mg/day) (62 subjects) ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · February 2005
The Cord Blood Transplantation study group conducted a prospective study of unrelated cord blood transplantation (CBT) to better define the role of this stem cell source for subjects requiring unrelated allogeneic transplantation. We report on 1 stratum of ...
Full textLink to itemCite
Journal articleCytotherapy · 2005
Allogeneic stem cell transplantation (alloSCT), especially in the mismatched setting, carries a high risk of life-threatening GvHD because of activation of donor T cells by Ag present on host cells. Removal of mature donor T cells can prevent GvHD but lead ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · January 2005
We conducted a phase II trial in 19 chronic graft-versus-host disease (cGVHD) patients with rapamycin, calcineurin inhibitors, and prednisone with the goals of controlling cGVHD, reducing prednisone use, and defining the safety of this regimen. Rapamycin w ...
Full textLink to itemCite
Journal articleClin Cancer Res · November 1, 2004
PURPOSE: To evaluate the safety of concurrent treatment with trastuzumab and high-dose chemotherapy (HDC), using cyclophosphamide, cisplatin, and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), with autologous hematopoietic progenitor cells support, in patien ...
Full textLink to itemCite
Journal articleBlood · August 1, 2004
We report a phase 1 study of pharmacokinetics, dosimetry, toxicity, and response of (131)I anti-tenascin chimeric 81C6 for the treatment of lymphoma. Nine patients received a dosimetric dose of 370 MBq (10 mCi). Three patients received an administered acti ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · August 2004
We report the outcome of 13 patients with advanced malignancies who underwent nonmyeloablative conditioning therapy followed by infusion of partially matched unrelated cord blood cells. The median age of these patients was 49 years, and their median weight ...
Full textLink to itemCite
Journal articleChest · August 2004
Noninfectious pulmonary complications are one of the major side effects of hematopoetic stem cell transplant (HSCT); however, the development of pulmonary sarcoidosis post-HSCT is uncommon, with only three cases previously reported. In each of those cases, ...
Full textLink to itemCite
Journal articleCancer · June 1, 2004
BACKGROUND: Many patients with recurrent, intermediate or high-grade non-Hodgkin lymphoma (NHL) may not respond to or are not candidates for aggressive salvage chemotherapy. Effective, less toxic regimens are needed. Although high-dose taxanes have not bee ...
Full textLink to itemCite
Journal articleBlood · June 1, 2004
In the current study, we tested whether higher numbers of hematopoietic stem cells correlate with the speed of immune reconstitution in a congenic transplantation model (C57BL/Ka, CD45.1, Thy1.1-->C57BL/6, CD45.2, Thy1.2) using purified hematopoietic stem ...
Full textLink to itemCite
Journal articleAm J Surg Pathol · June 2004
Posttransplantation lymphoproliferative disorder (PTLD) is a well-recognized complication of conventional bone marrow/stem cell and solid organ transplantation. However, not much is known about PTLD following the more recently introduced nonmyeloablative a ...
Full textLink to itemCite
Journal articleLeuk Res · June 2004
The invasion and colonization of oral cavity mucosal tissues by microflora may contribute to the pathophysiology of ulcerative oral mucositis (UOM). Iseganan is an analog of protegrin-1, a naturally occurring peptide with broad-spectrum microbicidal activi ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · April 2004
Minor histocompatibility antigens (miHA) are responsible for the occurrence of graft-versus-host disease in the setting of a major histocompatibility complex matched sibling allogeneic stem cell transplantation. These miHA are peptide fragments that are as ...
Full textLink to itemCite
Journal articleBone Marrow Transplant · March 2004
The current study assessed renal function based on medical records in adult hematopoietic stem cell transplant (HSCT) recipients with proven or probable invasive fungal infection (IFI) transplanted between 1995 and 2000. We confirm that amphotericin B deox ...
Full textLink to itemCite
Journal articleBlood · February 15, 2004
The major challenge in allogeneic hematopoietic cell transplantation is how to transfer allogeneic T-cell immunity without causing graft-versus-host disease (GVHD). Here we report a novel strategy to selectively prevent GVHD by depleting CD62L(+) T cells ( ...
Full textLink to itemCite
Journal articleHematology Am Soc Hematol Educ Program · 2004
Allogeneic stem cell transplantation is an accepted treatment modality for selected malignant and non-malignant diseases. However, the ability to identify suitably matched related or unrelated donors can be difficult in some patients. Alternative sources o ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · January 2004
Unrelated umbilical cord blood (UCB) transplantation has recently been explored in an increasing number of adult patients. The relative ease of procurement and the lower-than-anticipated risk of severe acute graft-versus-host disease has made UCB transplan ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · December 2003
Since January 1996, we have administered myeloablative therapy followed by infusion of unrelated umbilical cord blood cells in 57 adult patients with high-risk disease. The median age was 31 years (range, 18-58 years), and the median weight was 70 kg (rang ...
Full textLink to itemCite
Journal articleLeuk Lymphoma · November 2003
Graft versus Host Disease (GVHD) is the principal cause of morbidity and mortality in patients undergoing allogeneic stem cell transplant. T cell depletion has been recognized as a method of reducing the incidence of GVHD in allogeneic transplants. Until r ...
Full textLink to itemCite
Journal articleExp Hematol · October 2003
OBJECTIVE: To test in a murine model whether recombinant human growth hormone can promote immune recovery after allogeneic T-cell-depleted bone marrow transplantation. MATERIALS AND METHODS: Lethally irradiated (8.5 Gy) BALB/c mice (H2(d)) were transplante ...
Full textLink to itemCite
Journal articleBlood · June 15, 2003
Allogeneic stem cell transplantation with umbilical cord blood (UCB) cells is limited by the cell dose a single unit provides recipients. Ex vivo expansion is one strategy to increase the number of cells available for transplantation. Aastrom Biosciences d ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · March 2003
We have performed a phase I dose escalation of 4-Hydroperoxycyclophosphamide (4HC) purging of autologous peripheral blood progenitor cells (PBPCs) to improve the outcome of autologous transplantation for patients with myeloid leukemia. Peripheral blood ste ...
Full textLink to itemCite
Journal articleClin Cancer Res · February 2003
PURPOSE: The purpose of this study was to determine the maximum tolerated duration of infusion of gemcitabine at 10 mg/m(2)/min in combination with fludarabine at 25 mg/m(2) daily for 5 days in the treatment of relapsed or refractory acute myelogenous leuk ...
Link to itemCite
Journal articleHematology Am Soc Hematol Educ Program · 2003
After allogeneic stem cell transplantation, the establishment of the donor's immune system in an antigenically distinct recipient confers a therapeutic graft-versus-malignancy effect, but also causes graft-versus-host disease (GVHD) and protracted immune d ...
Full textLink to itemCite
Journal articleJ Hematother Stem Cell Res · August 2002
Featured Publication
Nonmyeloablative allogeneic stem cell transplantation (NMSCT) may destroy some malignancies through a graft-versus-tumor (GVT) effect, but tumor relapse and viral reactivation remain challenges for which immunizations may be helpful. Dendritic cells (DC), ...
Full textLink to itemCite
Journal articleBlood · May 1, 2002
Featured Publication
In this study, we investigated the possibility of selective depletion of donor alloantigen-specific T cells from C57BL/6 (H-2(b)) mice to prevent graft-versus-host disease (GVHD). These cells were first activated with irradiated BALB/c (H-2(d)) host spleen ...
Full textLink to itemCite
Journal articleLeuk Lymphoma · May 2002
Featured Publication
Twenty-three adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia (PLL) were treated for up to 12 weeks with the anti-CD52 monoclonal antibody alemtuzumab. Patients were a median of six years from diagnos ...
Full textLink to itemCite
Journal articleCytokine · April 7, 2002
Featured Publication
Treatment with myeloablative chemotherapy and autologous peripheral blood stem cell (PBSC) transplantation followed by vaccination with autologous dendritic cells (DCs) treated with tumor antigens is a promising therapeutic strategy for several types of ca ...
Full textLink to itemCite
Journal articleDrugs of the Future · March 26, 2002
Triptolide is a diterpenoid triepoxide purified from Tripterygium wilfordii Hook F, an herb found in China. Triptolide inhibits T cell activation mainly through inhibition of interleukin-2 production. In contrast to the target of ciclosporin and FK506, the ...
Full textCite
Journal articleBlood · March 15, 2002
Featured Publication
Significant delays in engraftment and lymphoid recovery are the 2 major challenges in cord blood transplantation. The cause for this delay is presumed to be the low numbers of hematopoietic precursors found in one unit of cord blood. One approach to increa ...
Full textLink to itemCite
Journal articleTransplantation · January 15, 2002
Featured Publication
BACKGROUND: PG490-88, a semisynthetic derivative of a novel compound PG490 (triptolide) purified from a Chinese herb (Tripterygium wilfordii Hook F), is effective in prevention of murine graft-versus-host disease (GVHD). METHODS: PG490-88 was administrated ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · 2002
Featured Publication
T-cell recovery following myeloablative preparatory regimens and cord blood transplantation in adult patients gen erally occurs between 1 and 3 years following allogeneic bone marrow transplantation. T-cell reconstitution may involve thymic education of do ...
Full textLink to itemCite
Journal articleBlood · January 1, 2002
Featured Publication
Umbilical cord blood has been increasingly used as a source of hematopoietic stem cells. A major area of concern for the use of cord blood transplantation is the delay in myeloid and lymphoid recovery. To directly compare myeloid and lymphoid recovery usin ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · 2002
Despite modern chemotherapy, advanced breast cancer remains a significant cause of cancer morbidity and mortality in women. Patients with disease involvement of multiple lymph nodes represent a subgroup with a high risk of relapse. In particular, 50% of pa ...
Full textLink to itemCite
Journal articleBlood · December 1, 2001
Featured Publication
Reduction in the toxicity of allogeneic transplantation with nonmyeloablative induction regimens has expanded the scope of practice to older and more debilitated patients. However, the limited availability of matched sibling donors requires that alternativ ...
Full textLink to itemCite
Journal articleExp Hematol · March 2001
Featured Publication
Acute graft-vs-host disease (GVHD) is a major obstacle to safe allogeneic hematopoietic stem cell transplantation (HSCT), leading to a significant morbidity and mortality. GVHD occurs when transplanted donor T lymphocytes react to foreign host cells. It ca ...
Full textLink to itemCite
Journal articleBlood · January 15, 2001
Featured Publication
Advanced stage follicular small cleaved and mixed cell lymphoma is characterized by relapse from remission and survival ranging from 6 to 12 years. Because young patients have the greatest compromise in longevity, the efficacy and toxicity of high-dose rad ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · 2001
Featured Publication
MSL-109 is a monoclonal antibody specific to the cytomegalovirus (CMV) glycoprotein H with high neutralizing capacity. In a prospective, randomized, double-blind study, allogeneic hematopoietic stem cell transplantation (HSCT) recipients with positive dono ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · 2001
Featured Publication
T-cell reconstitution following allogeneic stem cell transplantation may involve thymic education of donor-derived precursors or peripheral expansion of mature T cells transferred in the graft. T cell-receptor excision circles (sjTRECs) are generated withi ...
Full textLink to itemCite
Journal articleMol Ther · January 2001
Immunization with defined tumor antigens is limited to the small number of cancers in which specific tumor antigens have been defined but insufficient tumor material is available to produce an antitumor vaccine. In this study, we investigated whether pulsi ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · 2001
High-dose CBV (cyclophosphamide, carmustine, and etoposide) in combination with autologous HCT achieves survival rates of approximately 50% at 5 years in recurrent or refractory Hodgkin's disease (HD). However, carmustine (BCNU) dose-dependent pulmonary to ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · 2001
PURPOSE: To evaluate the efficacy of inhaled fluticasone propionate (Flovent) as prophylaxis against delayed pulmonary toxicity syndrome (DPTS) and decline in pulmonary function in breast cancer patients undergoing high-dose chemotherapy with the condition ...
Full textLink to itemCite
Journal articleBlood · December 1, 2000
PG490-88 is a semisyntheüc derivative of a novel compound PG490 (triptolide) purified from a Chinese herb (Tripterygium Wilfordii Hook F). Host specific tolerance in vivo was demonstrated in PG490-88-treated BALB/c recipients (H2d, Mls-21, Mls-3") of bone ...
Cite
Journal articleBlood · December 1, 2000
Umbilical cord blood is a valuable source of hematopoietic stem cells. However, stem cell numbers are limited and there are significant delays in engraftment and immune reconstitution. Since full matching at the major histocompatibility complex (MHC) appea ...
Cite
Journal articleTransplantation · November 27, 2000
Featured Publication
BACKGROUND: PG490-88 is a water soluble, semisynthetic derivative of a novel compound PG490 (triptolide) purified from the Chinese herb Tripterygium Wilfordii Hook F. METHODS: PG490-88 was administrated into recipient mice in a model (B10.D2-->BALB/c) of l ...
Full textLink to itemCite
Journal articleBone Marrow Transplant · October 2000
Featured Publication
The use of cyclosporin A has been associated with several side-effects, including neurotoxicity. The mechanism of toxicity is not well known. We report two patients treated with cyclosporin A who developed lesions in the cerebral white matter associated wi ...
Full textLink to itemCite
Journal articleJ Vasc Interv Radiol · October 2000
Featured Publication
PURPOSE: To determine the safety and efficacy of the conversion of subcutaneous chest wall infusion ports to tunneled central venous catheters. MATERIALS AND METHODS: During a period of 34 months, 67 patients were referred for conversion of indwelling subc ...
Full textLink to itemCite
Journal articleBlood · January 15, 2000
Featured Publication
PG27, an active fraction purified from an extract of a Chinese herb, Tripterygium wilfordii hook f, was used to prevent graft-versus-host disease (GVHD) in a murine model. Lethally irradiated BALB/c (H-2(d)) recipients of B10.D2 (H-2(d)) donor grafts were ...
Link to itemCite
Journal articleAm J Respir Crit Care Med · January 2000
Featured Publication
We closely followed the pulmonary function of 150 consecutive high-risk breast cancer patients who underwent standard induction CAF (cyclophosphamide, doxorubicin, 5-fluorouracil) chemotherapy, followed by randomization to either standard-dose CPB (cycloph ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · 2000
Featured Publication
Central nervous system (CNS) involvement by non-Hodgkin's lymphoma (NHL) carries a poor patient prognosis whether it occurs as a primary site of disease or secondarily in patients with systemic disease. In a group of 481 patients undergoing high-dose thera ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · 2000
Featured Publication
We have previously demonstrated a decrease in the incidence of acute graft-versus-host disease (GVHD) with the addition of methotrexate (MTX) to cyclosporine (CSP) and prednisone (PSE) chemotherapy in patients with leukemia. We have now completed a prospec ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · 2000
Featured Publication
Multiple-cycle high-dose therapy with autologous hematopoietic progenitor cell (AHPC) support has been used to deliver dose-intensive therapy. We have used this approach as well as single-cycle high-dose therapy in treating patients with metastatic breast ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · 2000
Featured Publication
Understanding the cellular mechanisms that lead to graft-versus-host disease (GVHD) may lead to alternative approaches in the prevention or therapy of this disease process. In this manuscript, we investigated the mechanisms of action of the immunosuppressi ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · 2000
Our purpose was to evaluate the outcome and costs of high-dose chemotherapy and autologous peripheral blood progenitor cell (PBPC) transplantation in patients with the inability to mobilize sufficient numbers of PBPCs to allow rapid engraftment after PBPC ...
Full textLink to itemCite
Journal articleClin Cancer Res · November 1999
Featured Publication
High-dose chemotherapy (HDCT) is currently under evaluation for high-risk primary breast cancer (HRPBC), defined by extensive axillary nodal involvement or inflammatory breast carcinoma. Phase II studies of HDCT for HRPBC show that 30-40% of patients event ...
Link to itemCite
Journal articleClin Cancer Res · November 1999
Featured Publication
Dose-intensive chemotherapy appears to be important in the treatment of patients with recurrent solid tumors. Expanding upon our prior experience, we report the results of our most recent approach to administering dose-intensive therapy using four cycles o ...
Link to itemCite
Journal articleJ Clin Oncol · October 1999
Featured Publication
PURPOSE: We performed a retrospective review to determine predictive and prognostic factors in patients with metastatic breast cancer who received induction therapy, and, if they responded to treatment, high-dose chemotherapy. PATIENTS AND METHODS: Patient ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · 1999
Featured Publication
Graft-vs.-host disease (GVHD) is a major predictor of outcome following allogeneic bone marrow transplantation (BMT). For patients alive at day 100 after BMT, the presence or absence of chronic GVHD is one of the most important determinants of survival and ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · 1999
Featured Publication
Graft-vs.-host disease (GVHD) remains the major toxicity of allogeneic bone marrow transplantation. Mechanistic studies in experimental animal models provide a better understanding of the complex relationships and cascade of events mediated by cellular and ...
Full textLink to itemCite
Journal articleJ Clin Oncol · March 1998
Featured Publication
PURPOSE: To determine the incidence of myelodysplasia (MDS) and/or acute leukemia (AL) in breast cancer patients after high-dose chemotherapy (HDC) with a single conditioning regimen and autologous bone marrow transplant (ABMT), and analyze the cytogenetic ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · December 1997
Featured Publication
Myeloablative therapy followed by allogeneic bone marrow transplantation (BMT) has proven to be curative therapy in patients with hematologic malignancies. Relapse, however, remains a major cause of treatment failure for patients with advanced disease. Dur ...
Link to itemCite
Journal articleAm J Surg Pathol · September 1997
Featured Publication
Skin biopsies are commonly performed after allogeneic bone marrow transplantation (BMT) to help establish the origin of a new skin rash in a transplant recipient. Histologic criteria and a grading system for acute graft-versus-host reaction of the skin are ...
Full textLink to itemCite
Journal articleCurr Opin Oncol · September 1997
Featured Publication
Standard therapies for advanced low-grade lymphomas are not likely to provide a cure, prompting the use of more aggressive approaches. Patients with low-grade lymphoma who receive high-dose therapy with stem cell support appear to have a prolonged disease- ...
Full textLink to itemCite
Journal articleBlood · August 15, 1997
Featured Publication
The precise role of the endogenous immune system in modulating cancer development remains unclear. Tumor cells are generally thought to be nonimmunogenic because they are of 'self' origin. However, tumor-reactive lymphocytes can be isolated from patients w ...
Link to itemCite
Journal articleImmunol Lett · July 1997
Featured Publication
Graft-versus-host disease (GVHD), which occurs when donor T-cells recognize multiple minor host histocompatibility antigens as non-self, presents the major limitation to successful allogeneic bone-marrow transplantation. The synthetic random copolymer of t ...
Full textLink to itemCite
Journal articleBlood · February 15, 1997
Featured Publication
The CD31 monoclonal antibody, LYP21, binds to the CD31 domain 6 and inhibits the human mixed-lymphocyte reaction (MLR) in a specific and dose-dependent fashion. A synthetic CD31 peptide based on human CD31 epitope (amino acids 551 to 574) recognized by LYP ...
Link to itemCite
Journal articleBlood · February 1, 1997
Featured Publication
One hundred nineteen patients with relapsed or refractory Hodgkin's disease (HD) received high-dose therapy followed by autologous hematopoietic progenitor cell transplantation. Three preparatory regimens, selected on the basis of prior therapy and pulmona ...
Link to itemCite
Journal articleJ Clin Oncol · January 1997
Featured Publication
PURPOSE: To determine the effect of age on the outcome of autologous bone marrow transplantation (ABMT) and/or peripheral-blood progenitor-cell (PBPC) transplantation. PATIENTS AND METHODS: A retrospective analysis was performed on 500 consecutive patients ...
Full textLink to itemCite
Journal articleCancer · December 15, 1996
Featured Publication
BACKGROUND: A number of studies have demonstrated that high dose chemotherapy, with or without radiotherapy, with autologous marrow and/or peripheral blood progenitor cell support can result in improved overall and complete response rates in patients with ...
Full textLink to itemCite
Journal articleLeuk Lymphoma · September 1996
Featured Publication
Graft-versus-host disease (GVHD) represents the major barrier to successful allogeneic bone marrow transplantation. Positive and negative selection studies have unequivocally demonstrated that donor T cells are responsible for the induction phase of GVHD. ...
Full textLink to itemCite
Journal articleMedicine (Baltimore) · September 1996
Featured Publication
A syndrome indistinguishable from idiopathic polymyositis occurred in 11 patients as a manifestation of chronic GVHD. All patients had elevation of creatine phosphokinase (CPK). Immunohistology demonstrated the effector cells in the muscle infiltrates as c ...
Full textLink to itemCite
Journal articleProc Natl Acad Sci U S A · May 14, 1996
Featured Publication
Graft-versus-host disease (GVHD) is a T-cell-mediated disease of transplanted donor T cells recognizing host alloantigens. Data presented in this report show, to our knowledge, for the first time that a synthetic copolymer of the amino acids L-Glu, L-Lys, ...
Full textLink to itemCite
Journal articleBiol Blood Marrow Transplant · May 1996
Featured Publication
Thalidomide has been reported to be an effective agent for the treatment of chronic graft-vs.-host disease (GVHD). To determine its efficacy as a prophylactic agent for the prevention of chronic GVHD, a prospective randomized double-blind study was perform ...
Link to itemCite
Journal articleBiol Blood Marrow Transplant · May 1996
Featured Publication
The use of high-dose chemotherapy with or without total-body irradiation (TBI) followed by autologous hematopoietic cell transplantation is associated with improved survival for relapsed or refractory non-Hodgkin's lymphoma (NHL). Previous reports comparin ...
Link to itemCite
Journal articleN Engl J Med · February 1, 1996
Featured Publication
BACKGROUND: Graft-versus-host disease (GVHD) caused by poorly defined minor (i.e., other than HLA) histocompatibility antigens remains a serious problem in recipients of bone marrow transplants. We sought to determine whether the CD31 adhesion molecule is ...
Full textLink to itemCite
Journal articleCancer Chemother Pharmacol · 1996
Featured Publication
PURPOSE: CCNU (lomustine) and other nitrosourea compounds are rapidly metabolized to alkylating moieties, which are active against various malignancies. In humans, CCNU undergoes biotransformation to the geometric isomers of 4'-hydroxyCCNU. The pharmacokin ...
Full textLink to itemCite
Journal articleAnn N Y Acad Sci · December 29, 1995
Featured Publication
Graft-versus-host disease remains a formidable barrier in allogeneic bone marrow transplantation. Studies have shown that effective prophylaxis results in improved overall survival for patients following allogeneic bone marrow transplantation. Various meth ...
Full textLink to itemCite
Journal articleCan J Oncol · December 1995
Featured Publication
The anti-tumor effect and toxicity of chemotherapeutic agents are dose-related. The dose-response curve for these agents is sigmoidal with a threshold, a lag phase, a linear phase and a plateau phase. The aim of cancer chemotherapy is to exploit the differ ...
Link to itemCite
Journal articleBiol Blood Marrow Transplant · December 1995
Featured Publication
The use of ganciclovir at the time of cytomegalovirus (CMV) infection but before disease onset has been termed "preemptive" therapy. This preemptive ganciclovir administration has been shown to be an effective method for preventing severe CMV disease after ...
Link to itemCite
Journal articleJ Clin Oncol · December 1995
PURPOSE: A non-radiation-containing regimen of busulfan and cyclophosphamide (BU/CY) was evaluated for toxicity, relapse, and long-term survival in patients who received allogeneic bone marrow transplantation (BMT) for myelodysplasia (MDS). PATIENTS AND ME ...
Full textLink to itemCite
Journal articleBlood · November 1, 1995
Thalidomide has been reported to be an effective agent for treatment of chronic graft-versus-host disease (CGVHD). To determine the efficacy of this agent in patients with refractory CGVHD a total of 80 patients who failed to respond to prednisone (PSE) or ...
Link to itemCite
Journal articleJ Immunol · October 15, 1995
Featured Publication
Activation of T cells leading to graft-vs-host disease (GVHD) requires two signaling events: the Ag-specific signal generated through the engagement of the TCR/CD3 complex with antigenic peptide fragments presented by MHC molecules on APCs and the second s ...
Link to itemCite
Journal articleCancer · September 1, 1995
Featured Publication
BACKGROUND: Retrospective studies suggest that dose intensity is an important determinant of outcome in the treatment of patients with a variety of malignant diseases such as breast cancer, ovarian cancer, and lymphoma. Unfortunately, these results have no ...
Full textLink to itemCite
Journal articleExp Hematol · August 1995
Featured Publication
The exact mechanism of immunosuppression by thalidomide is poorly understood. A common denominator in the pathogenesis of graft-vs.-host disease, graft rejection, reactional lepromatous leprosy, and autoimmune disorders modulated by thalidomide is the acti ...
Link to itemCite
Journal articleBlood · June 1, 1995
Featured Publication
High-dose chemotherapy with or without radiotherapy followed by autologous transplantation of hematopoietic progenitor cells is an effective treatment for patients with high-risk or relapsed non-Hodgkin's lymphoma. Chemotherapy and/or hematopoietic growth ...
Link to itemCite
Journal articleCancer · March 15, 1995
Featured Publication
BACKGROUND: This trial studied the feasibility and efficacy of a new preparatory regimen for autologous bone marrow transplantation for patients with advanced lymphoid malignancies. METHODS: Twenty-one patients with Hodgkin's disease (n = 12) and non-Hodgk ...
Full textLink to itemCite
Journal articleJ Clin Oncol · December 1994
PURPOSE: High-dose etoposide was incorporated into a regimen of fractionated total-body irradiation (FTBI) and high-dose cyclophosphamide before autologous transplant with the goal to enhance the antitumor effect of the myeloablative regimen in poor-risk l ...
Full textLink to itemCite
Journal articleBlood · October 15, 1994
Featured Publication
Graft-versus-host disease across minor histocompatibility barriers was induced in two different models by transplanting allogeneic bone marrow and spleen cells into irradiated H-2-compatible recipient mice. In this report, we show that administration of pe ...
Link to itemCite
Journal articleBlood · September 1, 1994
Ninety-four consecutive patients with chronic myelogenous leukemia in first clinical chronic phase, median age of 34.0 years (range, 6.8 to 52.4 years), with a histocompatible sibling donor, were treated with fractionated total body irradiation (1,320 cGy) ...
Full textCite
Journal articleBlood · September 1, 1994
Featured Publication
Hematopoietic growth factors have been shown to be effective in reducing the period of neutropenia after autologous bone marrow transplantation (BMT). Initial concerns over potential aggravation of graft-versus-host disease (GVHD) and increase in the incid ...
Link to itemCite
Journal articleBlood · September 1, 1994
Featured Publication
Ninety-four consecutive patients with chronic myelogenous leukemia in first clinical chronic phase, median age of 34.0 years (range, 6.8 to 52.4 years), with a histocompatible sibling donor, were treated with fractionated total body irradiation (1,320 cGy) ...
Link to itemCite
Journal articleBlood · May 15, 1994
Featured Publication
Anemia is a universal finding in patients undergoing autologous bone marrow transplantation (BMT). Effective therapies to increase the number of autologous red blood cells could result in a lower morbidity and mortality associated with red blood cell trans ...
Link to itemCite
Journal articleBone Marrow Transplant · 1994
Featured Publication
In 1983, we began a series of clinical trials with the goal of reducing the relapse rate following allogeneic BMT for hematologic malignancies. Because of its anti-leukemic activity, the drug VP-16 was chosen and combined with total body irradiation (TBI). ...
Link to itemCite
Journal articleBlood · November 1, 1993
Featured Publication
Ninety-nine consecutive patients with acute leukemia in first complete remission under age 50 (median age 27 years; age range 1 to 47 years) with a histocompatible sibling donor were treated with fractionated total body irradiation (1,320 cGy) and high-dos ...
Link to itemCite
Journal articleN Engl J Med · October 21, 1993
Featured Publication
BACKGROUND: Acute graft-versus-host disease (GVHD) following allogeneic bone marrow transplantation remains a serious problem. In a clinical trial, we tested the combination of cyclosporine and prednisone with and without methotrexate for the prevention of ...
Full textLink to itemCite
Journal articleLeukemia · October 1993
Featured Publication
Cloned colony-stimulating factors have been shown to accelerate myeloid recovery following autologous bone marrow transplantation. Studies with granulocyte-macrophage colony-stimulating factor (GM-CSF) have demonstrated efficacy in accelerating neutrophil ...
Link to itemCite
Journal articleBlood · April 15, 1993
Featured Publication
Hematopoietic growth factors have been used to accelerate engraftment after bone marrow transplantation and to "mobilize" peripheral blood progenitor cells (PBPC). We report on the data in 85 consecutive patients with Hodgkin's disease who were treated in ...
Link to itemCite
Journal articleTransplantation · March 1993
Featured Publication
A group of 235 allogeneic marrow recipients were contacted at least one year following their BMT to obtain information on their quality of life; 212 (90%) agreed to participate in this survey. A total of 162 adults and 50 pediatric survivors were interview ...
Full textLink to itemCite
Journal articleBlood · January 15, 1993
Featured Publication
Current intensive chemotherapy for acute nonlymphoblastic leukemia (ANLL) results in a complete remission in the majority of patients. Unfortunately, the duration of remission is short and most of the patients will experience a relapse of their underlying ...
Link to itemCite
Journal articleCancer Chemother Pharmacol · 1993
Featured Publication
The methoxymorpholino derivative of doxorubicin (MMDX; FCE 23672) has recently entered clinical trials because of its broad spectrum of preclinical antitumor activity and non-cross-resistance in multidrug-resistant (MDR) tumor models. MMDX is activated in ...
Full textLink to itemCite
Journal articleCurr Opin Immunol · October 1992
Featured Publication
Graft versus host disease is a major barrier in allogeneic bone marrow transplantation. The associated morbidity and mortality need to be understood and prevented if possible, as the potential indications for bone marrow transplantation continue to broaden ...
Full textLink to itemCite
Journal articleExp Hematol · October 1992
Featured Publication
Cyclosporin (CsA) is a potent modulator of multidrug resistance (MDR) and has been combined with etoposide (VP-16) to purge MDR leukemic cells from human bone marrow (BM) in vitro. We studied the feasibility of this approach in an in vivo model for autolog ...
Link to itemCite
Journal articleBlood · August 1, 1992
Featured Publication
To determine the quality of life in adult patients after autologous bone marrow transplantation (BMT), we administered a questionnaire to a cohort of patients seen at a single referral-based center. The sample included adults 18 years and older during the ...
Link to itemCite
Journal articleBr J Haematol · June 1992
Featured Publication
The multidrug resistance gene mdr1, encoding P-glycoprotein (P-gp), can be expressed at high levels in tumour cells derived from normal tissues with constitutive high expression of this gene. In myelogenous leukaemia, the incidence of increased expression ...
Full textLink to itemCite
Journal articleAnn Intern Med · February 1, 1992
Featured Publication
OBJECTIVE: To determine the hemopoietic effects of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients having autologous hemopoietic stem cell transplantation for Hodgkin or non-Hodgkin lymphoma. DESIGN: Placebo or GM-CS ...
Full textLink to itemCite
Journal articleTransfusion · January 1992
Featured Publication
The in vitro and in vivo effects of cryopreservation on the cytotoxic activity of murine lymphokine-activated killer (LAK) cells were studied. LAK cells were generated by incubation of spleen lymphocytes of BALB/c mice for 3 days with recombinant interleuk ...
Full textLink to itemCite
Journal articleBlood · October 15, 1991
Featured Publication
Fifty-three patients with high-risk acute lymphoblastic leukemia (ALL) under age 50 with a histocompatible sibling donor received high-dose radiochemotherapy followed by allogeneic bone marrow transplantation (BMT). The high-risk factors used to identify t ...
Link to itemCite
Journal articleJ Clin Oncol · September 1991
Featured Publication
The survival of patients with acute leukemia who do not achieve a remission with primary therapy is very poor. High-dose chemoradiotherapy followed by allogeneic bone marrow transplantation (BMT) has been shown to be effective therapy for patients with acu ...
Full textLink to itemCite
Journal articleJ Clin Oncol · September 1991
Featured Publication
Alkylating agents used either with or without radiation therapy have been associated with the development of myelodysplastic syndrome (MDS) and acute nonlymphoblastic leukemia (ANLL) after treatment of both malignant and nonmalignant disorders. This report ...
Full textLink to itemCite
Journal articleBlood · May 1, 1991
Featured Publication
Selective removal of malignant cells (purging) from bone marrow (BM) is a concern in autologous BM transplantation (ABMT). Use of vincristine, etoposide, or doxorubicin for purging could be rendered ineffective by the presence of multidrug-resistant (MDR) ...
Link to itemCite
Journal articleNew England Journal of Medicine · 1991
Background. Cytomegalovirus (CMV)-associated interstitial pneumonia is a major cause of death after allogeneic bone marrow transplantation. We conducted a controlled trial of ganciclovir in recipients of bone marrow transplants who had asymptomatic pulmona ...
Cite
Journal articleAnn Oncol · January 1991
Featured Publication
Seventy-seven Hodgkin's disease and non-Hodgkin's lymphoma (NHL) patients received high-dose etoposide in combination with cyclophosphamide and either fractionated total body irradiation (TBI) (n = 28) or carmustine (n = 49) prior to autologous bone marrow ...
Full textLink to itemCite
Journal articleExp Hematol · December 1990
Featured Publication
We studied the effects of two modulators of multidrug resistance (MDR), cyclosporine and verapamil, on the cytotoxicity of etoposide (VP-16) in normal human bone marrow; two human leukemia cell lines, K562 and CEM; their MDR variants, K562/DOX and CEM/VLB; ...
Link to itemCite
Journal articleBlood · October 1, 1990
Featured Publication
Eighty-three patients with intermediate- or high-grade non-Hodgkin's lymphoma were treated with CEPP(B) (cyclophosphamide, etoposide [VP-16], procarbazine, and prednisone with or without bleomycin) chemotherapy at Stanford University Medical Center (Stanfo ...
Link to itemCite
Journal articleExp Hematol · September 1990
Featured Publication
We studied the effects of two modulators of multidrug resistance (MDR), cyclosporine and verapamil, on the cytotoxicity of etoposide (VP-16) in normal bone marrow cells. VP-16 was toxic to normal bone marrow at concentrations greater than 50 microM, result ...
Link to itemCite
Journal articleClin Transpl · 1990
Featured Publication
Allogeneic and autologous BMTs are highly effective and successful treatment modalities for selected patients. Use of BMT earlier in the course of disease yields better results when compared to patients with more advanced disease. Recent advances such as u ...
Link to itemCite
Journal articleWest J Med · January 1990
Featured Publication
Autologous bone marrow transplantation provides an effective form of "rescue" following high-dose therapy used for treating certain malignant diseases. The high doses of radiotherapy or chemotherapy, or both, should allow for greater tumor cell kill if dos ...
Link to itemCite
Journal articleJ Immunol Methods · December 20, 1989
Featured Publication
The effect of cryopreservation on the cytotoxic activity of lymphokine-activated killer (LAK) cells was studied. LAK cells were generated by incubating peripheral blood lymphocytes for 3-5 days with recombinant interleukin-2 (rIL-2) and then cryopreserved ...
Full textLink to itemCite
Journal articleWest J Med · December 1989
Featured Publication
Major progress in experimental and clinical research has made allogeneic bone marrow transplantation a highly effective therapy for a variety of malignant and nonmalignant diseases. Allogeneic bone marrow transplantation from histocompatible donors is now ...
Link to itemCite
Journal articleImmunogenetics · 1989
Featured Publication
The BB or BB/Worcester (BB/W) rat is widely recognized as a model for human insulin-dependent diabetes mellitus (IDDM). Of at least three genes implicated in genetic susceptibility to IDDM in this strain, one is clearly linked to the major histocompatibili ...
Full textLink to itemCite
Journal articleScience · May 20, 1988
Class II major histocompatibility (MHC) molecules have an immunoregulatory role. These cell-surface glycoproteins present fragments of protein antigens (or peptides) to thymus-derived lymphocytes (T cells). Nucleotide sequence polymorphism in the genes tha ...
Full textLink to itemCite
Journal articleJ Clin Oncol · February 1987
With improvement and refinement of therapy, the majority of Hodgkin's disease patients are alive and free of disease at 5 years. As these patients continue to be observed, a variety of late complications have been reported. We describe herein three patient ...
Full textLink to itemCite
Journal articleJ Exp Med · March 1, 1982
Immunized Ly-1+2-T cells (Ly-1 cells) make an antigen-specific soluble suppressor product (Lyl-1 TsiF) that will induce Ly-2+ cells to express suppressive activity but only if the Ly-2+ and the Ly-1 producer cell share genetic polymorphisms that are linked ...
Full textLink to itemCite